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SUMMARY 
Treatment of brain and nervous system cancers remains a daunting clinical 
challenge, with one of the most common brain malignancies, glioblastoma, incurring a 
mere 5% five-year survival rate. In the search for new therapeutic means—specifically, 
new ways to direct or curb the invasion of brain cancers—we investigate the directed 
invasion of brain cancer cellular aggregates by an electrical field. This property is known 
as electrotaxis (or galvanotaxis), and is known to be involved in a variety of endogenous 
phenomena including tissue development and wound healing, and is purported to be 
involved in cancer invasion and metastasis. In this study, we explore electrotaxis in the 
context of brain cancer, and provide new insights into the effect’s underlying 
mechanisms. 
Here, we have developed an electrotaxis assay that adapts existing cancer 
invasion assays and allows us to study electrotaxis on aggregated populations of cells. 
We characterize glioblastoma and medulloblastoma cell lines in these assays and report 
on their electrotactic properties. We then investigate the transcriptome for two cell lines 
that were found to have opposing electrotactic responses, followed by pharmacological 
inhibition studies to further validate some of our findings. Overall, the hypotheses 
explored in this work advance our understanding of the pathways that underlie 




CHAPTER 1. INTRODUCTION 
1.1 Brain malignancies remain a critical biomedical challenge 
Primary brain and nervous system cancers represent only a small proportion (1.4%) 
of total cancer incidence, however, these cancers are involved in proportionally twice as 
many cancer mortalities (2.8%) [Howlader, 2017]. For any given cancer, the mortality 
rate is on average 38% of incidence and the median overall 5-year survival rate is 65%. 
For brain cancers these rates are much worse: the mortality rate is 67% overall and the 
survival rates are 36% for primary and metastic tumors—21% once spread to lymph 
nodes. 
Neuroepithelial tumors represent the largest subcategory of malignant brain tumors, 
and are the most clinically pressing, as glioblastoma multiforme (GBM), the most 
common neuropithelial malignancy (46% of cases), bears a mere 5% five-year survival 
rate [Ostrom, 2015].  Along with mesotheleomia, the Cancer Genome Atlas data suggest 
that GBM is the least survivable cancer overall (Figure 1).  
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Figure 1. Survival probabilities of various cancer subtypes. Generated from the 
Cancer Genome Atlas (TCGA) clinical data, downloaded from the National Cancer 
Institute Genomic Data Commons (portal.gdc.cancer.gov) on September 17, 2017. 
Depicts survival probabilities including censored data and highlights the two brain cancer 
TCGA subtypes in red: glioblastoma multiforme (TCGA-GBM), and lower-grade glioma 
(TCGA-LGG). Also highlighted for comparison are the other lower survival rate cancers: 
mesothelioma (TCGA-MESO), acute myeloid leukemia (TCGA-LAML), uterine 
carcinosarcoma (TCGA-UCS), and pancreatic adenocarcinoma (TCGA-PAAD). 
 
Brain tumors are also one of the most prevalent pediatric malignancies, the most 
common of which, medulloblastoma (MB), is associated with 5-year survival rates as low 
as 48% [Crawford, 2007; Khanna, 2017]. These dismal survival rates are in part due to a 
lack of available therapies for cancers in neural tissues, a fact even more daunting when 
considering that 9-17% of all cancer patients will develop brain metastases [Nayak, 
2012]. 
The current clinical standard of care for brain malignancies is maximally-safe, 
surgical resection with concomitant fractionated radiotherapy, and chemotherapy 
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(typically oral Temozolomide and/or implantable Carmustine wafers) [Nabors, 2015]. 
The brain, however, is a particularly difficult organ to treat, as it is littered with eloquent, 
inoperable regions. These cancers often disseminate deep into neural tissue, making 
surgical resection not always possible when the tumor site corresponds to sensitive 
regions of the brain [Ricard, 2012; Wiesner, 2005]. Even if resection is possible, 
recurrence is common, due to an inability to completely eradicate all invasive fronts 
penetrating beyond the primary tumor core [Bernstein, 1995; Belail, 2004]. Systemic 
administration of chemotherapy is also challenging in the brain, as transport is restricted 
by physiological barriers to the blood stream and the resulting increased effective doses 
can be have undesirable effects on sensitive, healthy neural tissues, and can limit 
indication for geriatric or pediatric patients [Blakeley, 2008].  
Even with all the continued advances in drug discovery and delivery that have 
substantially improved outcomes in systemic cancers, there has been disappointingly 
little impact on tumors of the brain. Thus, there is an urgent need to innovate new 
strategies to safely manage or treat brain cancers and therein a substantial need for a 
better understanding of how brain tumor growth can be limited or controlled—in this 
work, we will look to electrical fields and their influence on cellular behavior as a means 
to do so. 
1.2 Electrotherapies for cancer 
There already exist a variety of electrical means for the treatment of cancer. 
However, the majority of these techniques do not circumvent the challenges seen with 
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resection and chemotherapy when applied for the brain. Figure 2 maps out these 
therapeutic strategies in terms of the field strengths and frequencies used. 
 
 
Figure 2. Regimes of electrotherapies for cancer. Adapted from [Marjanovič, 2011]. 
 
Thermal radiofrequency ablation works much like surgical resection in that it is 
used as a physical means of tumor de-bulking [Rossi, 1996]. Typically, two electrodes 
will be spaced across a tumor region and pulse trains provided with sufficient current to 
generate Joule heating. Tissue within the heated region is then indiscriminately ablated. 
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The technique can be applied non-invasively with the use of gold nanoparticles [Cardinal, 
2008] yet is limited in the brain by drug delivery barriers and a lack of precision in 
localizing/imaging tumors non-invasively.  
Nanosecond-pulsed electric fields [Nuccitelli, 2006] offer a similar strategy as 
thermal ablation, but without the thermal effect. Instead it is hypothesized that these 
fields are cell-penetrable and they create intracellular voltage gradients that disrupt 
organelle function. While this strategy has seen beneficial outcomes for melanoma, it is 
relatively unexplored for use in brain cancers, likely due to the same challenges 
encountered with thermal ablation. 
Electropermeabilization (sometimes referenced as electroporation in certain cases) 
also has found use in cancer therapy. Irreversible electropermeabilization makes use of 
localized, short duration pulse trains that violently disrupt cell membranes such that the 
cell is lysed [Davalos, 2005; Gehl, 2003]. This method possesses similar limitations as 
surgical intervention or targeted radiotherapy in that local access is required, and it can 
have indiscriminate effects on all tissues between the electrodes. Reversible 
electropermeabilization also uses localized, short duration pulses that gently 
permeabilizes or opens pores in the lipid membranes of cells such that the cells are only 
reversibly permeable. Electrochemotherapy [Gothelf, 2003; Mali, 2013] and electric gene 
transfer [Cukjati, 2007] are two therapeutic strategies that make use of this reversible 
regime, wherein the cellular uptake of a therapeutic substrate is enhanced. While these 
strategies do aid in decreasing the required effective dose of a chemotherapeutic, the 
requirement that a therapeutic have systemic access to the cells remains, which limits its 
use for brain cancers. 
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The cell-electrophoretic range, where the force of the electrical field is large 
enough to move a cell electro-kinetically, has been recently applied as a means to sort 
circulating tumor cells for isolation and detection [Shields, 2015]. However, the use of 
this technique is still experimental for central nervous system malignancies [Adamczyk, 
2015] and a therapeutic benefit has yet to be realized.  
There exists one clinically available brain tumor electrotherapy, tumor-treating 
fields, which uses low-power oscillatory electrical fields. The proposed mechanism of 
action is anti-mitotic; in that the fields are able to penetrate actively dividing cells 
through the cleavage formed during division, and disrupt the polar molecules involved in 
spindle formation, thus triggering apoptosis [Kirson, 2007]. The commercial device, 
know as Optune (formerly NovoTTF-100A) is FDA-approved for use in treating 
recurrent and newly diagnosed GBM with tandem administration of temozolomide. In a 
recent phase-III clinical trial (EF-14), Optune was shown to improve median overall 
survival in newly diagnosed GBM by 2.8 months (to 19.4 mos.) relative to chemotherapy 
alone (16.6 mos) [Stupp, 2015; Stupp, 2017]. Though, the overall outcomes are still 
bleak, especially in recurrent GBM where median survival with the device is still only 9.6 
mos [Stupp, 2012]. 
In the regime of low field-strength, non-oscillatory electrical fields, electrotaxis 
occurs, a regime largely unexplored for cancer therapy, and which is the primary regime 
focused on in this work. 
1.3 Electrotaxis 
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Electrotaxis (sometimes referred to as galvanotaxis), is the phenomenon whereby 
application of a low voltage, direct current, electrical field (dcEF) acts as a cue to direct a 
cell to move of its own volition [Funk, 2006; McCaig, 2009]. The concept of a non-
contact force being able to direct a cell’s motility is potentially interesting for brain 
cancer therapy when you consider that controlling invasion (or possibility undoing it) 
could be a major boon to the management of brain tumors. 
Electrotaxis has been observed as an endogenous response to physiologically-
generated electric fields (3-500 V/m) occuring during wound healing, neural 
development, and cancer invasion,  as part of the ensemble of simultaneous numerous 
chemical and physical cues in each process [Borgens, 1981; Mycielska, 2004; Song, 
2004; Nuccitelli, 2011; Chernet, 2013].  
Upon application of a dcEF, the phenomenon has been observed in myriad cell 
types, over a range of fields strengths, leading to a variety of cell-type specific responses 
that as of yet have no generalizeable, unifying mechanism [Cortese, 2014; Liu, 2014].  
In cancer research, electrotaxis was first explored as a way to characterize the 
metastatic potential of cells. Djamgoz, et al., compared two different prostate carcinoma 
cells lines, confirming a hypothesis that the more metastatic MatLyLu cells would 
respond to the physiological range of electric fields more strongly than the weakly 
metastatic AT-2 cells [Djamgoz, 2001]. Presuming the observed cathodally-directed 
(following the direction of positively charged particles in the dcEF) migration was 
voltage-gated channel mediated, tetrodotoxin was evaluated for its ability to knockout the 
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effect, though interestingly, tetrodotoxin only affected the highly metastatic line—the 
AT-2 cells still moved toward the cathode. 
The trend of more metastatic cells having stronger electrotactic response continued 
with work on metastatic breast cancers. The metatstatic MDA-MB-231 cell line displayed 
an anodal directionality (following the direction of negatively charged particles in the 
dcEF), compared with weakly metastatic MCF-7 cells that moved cathodally, albeit 
slower and with less sensitivity to the dcEF [Fraser, 2005]. This was surprising, as it was 
unexpected that cells of the same tissue type would have opposing directionality. It was 
later shown that the electrotactic response in breast cancers appears to correlate epidermal 
growth factor receptors (EGFR) expression [Pu, 2007]. In particular, with the MDA-MB-
231 cells, the response has been linked to the polarization of EGFRs onto the anodal cell 
membrane, and an increase of intracellular Ca2+ [Wu, 2013]. Though it remains unclear 
what leads to either an anodal or cathodal asymmetry, as it was previously shown that in 
certain cathodally-electrotaxing cells, EGFR polarization also can occur on the cathodal 
side [Zhao, 2002]. 
Human lung cancer cells have also shown similar electrotactic potential in 
correlation with metastatic potential. Huang, et al., used an electrotactic-sorting 
microfluidic system to show that metastatic CL1-5 cells respond anodally to a dcEF up to 
375 V/m, while the non-metastatic CL1-0 exhibited no electrotactic effect [Huang, 2009]. 
Primary brain cancer cell have only been used in a few electrotaxis studies, 
focusing mainly on mechanistic studies. U251 human GBM cells were shown to have a 
cathodal electrotactic response attributed to a voltage-gated potassium channel and 
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intracellular polyamines [Nakajima, 2015]. U251, U87mg (human GBM), and C6 (rat 
glioma) cell lines have also been found to electrotax toward the cathode and it was 
observed that this stimulated the production of hydrogen peroxide and superoxide [Li, 
2013]. It was then shown that superoxide was acting as an upstream regulator of the 
extracellular-signal-regulated kinase (ERK) and AKT pathways, which is thought to 
enable the direction persistence in some electrotaxing cells. 
Recently, Huang, et al., showed that the direction effect may be further altered by 
substrate or plating conditions. They tested 5 different brain-tumor-initiating cells plated 
on poly-L-lysine and laminin substrate, and found that under a dcEF, the cells all 
responded with a anodal preference, while fetal-derived neural progenitor cells responded 
cathodally [Huang, 2016]. When these same cells were plated in a 3-dimensional (3D) 
matrix of hyaluronic acid and collagen, the electrotactic response of the brain-tumor-
initiating cells reversed toward the cathode, but the authors presented no further evidence 
as to why this had occurred.  
It remains unclear, given any particular cell, whether it will be electrotactic, or in 
which direction it will move, and given the startling finding that substrate or plating 
conditions may dramatically alter the electrotactic response, there is a need for more 




CHAPTER 2. ELECTROTACTIC RESPONSES OF 
GLIOBLASTOMA AND MEDULLOBLASTOMA CELL 
SPHEROIDAL AGGREGATES 
2.1 Introduction 
Much of the previous work on electrotaxis has been focused on single-cell 
responses on 2D substrates, however, when cancerous tissues grow or invade in tissues, 
they may also do so as a collective or in 3D [Friedl, 2009].  
There have been few studies of electrotaxis at population or tissue densities. 
Babona-Pilipos, et al. studied neurospheres of subependymal neural precursors plated on 
a 2D substrate, but only analysed cells that had migrated sufficiently far from the rest of 
the neurosphere cohort [Babona-Pilipos, 2015]. Cohen, et al., developed methods to track 
individual cells in epithelial sheets of arbitrary geometries, as a way to piece apart the 
varied electrotactic responses of leader and follow cells [Cohen, 2014]. Lalli & Asthagiri 
showed, using densely-packed, 2D cultures of mammary epithelial cells that collective 
migration was more sensitive to dcEF (responding to 50% weaker fields than dispersed 
cells), yet the resulting electrotactic alignment occurred with slower dynamics [Lalli, 
2015]. 
One limitation to more population studies is that few cells truly form populations in 
2D. 3D electrotaxis studies have thus far been limited due to the inherent technical 
difficulties, but there have been a couple attempts of note. Zhang, et al., showed that 
dispersed human induced-pluripotent stem cells that were typically stationary in a 3D 
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matrix, responded cathodally to a physiological-level dcEF [Zhang, 2011]. Zhao, et al., 
developed a clever, high-throughput method of assaying cells in arrays of 3D agarose 
droplets with Dictyostelium cells, though this method has yet to be attempted for 
mammaliam cell culture [Zhao, 2013]. Spheroids have also been used as a 3D format 
though the studies have not included a 3D substrate and the spheroids have not been 
assessed for collective migration [Sauer, 2002; Babona-Pilipos, 2015]. Most recently, the 
above-mentioned study by Huang, et al., on brain-tumor initiating cells that had differing 
electrotactic responses in 3D and 2D, highlights the need for more studies that take into 
account experiments more than just 2D, single cell assays.  
In this chapter, we began with to study brain tumor cells undergoing electrotaxis in 
a population-level assay. We have attempted to marry the standard tumor invasion assay 
(e.g., [Vinci, 2015]) with previous work on standard electrotaxis assays [Song, 2007]. 
The design principles we chose to build for were: (i) flexible configuration, to allow 
many potential plating options; (ii) simplicity in fabrication; (iii) capability for long-term 
(>24h) experiments; and (iv) ability to analyze population-level changes without live-cell 
microscopy. We were able to develop for these requirements by fashioning systems out 
of standard 6-well tissue culture plates, with replaceable salt bridges, and simple dcEF 
sources to allow for constant incubation. Apart from the single-cell tracking experiments, 
we developed straightforward analytical methods to allow for analysis of population 
behavior without the need for live-cell imaging. We used these systems to determine how 
various brain tumor cell lines responded when plated as 3D spheroidal aggregates to 
dcEFs, as described below. 
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2.2 Materials & Methods 
2.2.1 in vitro cell culture and cell lines 
U87mg (human glioblastoma, ATCC HTB-14), DAOY (human medulloblastoma, 
ATCC HTB-186), and MatLyLu (rat prostate cancer, ATCC JHU-5) cells were obtained 
from ATCC. D283 Med (human medulloblastoma, ATCC HTB-185), D341 Med (human 
medulloblastoma, HTB-187), A-172 (human glioblastoma, ATCC CRL-1620), U373 
(human glioblastoma, ATCC HTB-17), T98G (human glioblastoma, ATCC CRL-1690), 
and LN229 (human glioblastoma, ATCC CRL-2611) cells were obtained from the Duke 
University Cell Culture Facility, all originally sourced from ATCC. All cells were 
maintained at 37ºC with 5% CO2 in Dulbecco’s Modified Eagle Medium (cellgro 15-
017CV) with 10% fetal bovine serum (Gemini 900-108), 1% L-Glutamine (Lonza 17-
605F), 1% Non-essential amino acids (cellgro 25-025-CI), and 1% penicillin-
streptomycin (Corning 30-001-CI).  Cells were passaged before confluence using 0.25% 
Trypsin-EDTA (gibco 25200-056). As noted for some experiments, U87mg and 
MatLyLu cells were made to stably express enhanced green fluorescent protein (GFP), 
via transfection with an GFP-expression plasmid using the Effectene Transfection 
Reagent (Qiagen 301425) and further selection of stable transfectants with G418 Sulfate 
(Gemini 400-113). 
2.2.2 Construction of electrotaxis chambers 
Corning 6-well plates (3516) were used as the basis for the chambers (Figure 3). 
The center two wells served as the plating region and media reservoirs. The outer four 
wells served as buffer reservoirs and electrode-electrolyte transition wells. The three 
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wells of each row were coupled so that two assays could be performed on a single plate. 
Platinum electrodes (Omega Engineering SPPL-008) were used in an electrolyte bath of 
phosphate buffered solution (Corning 21-040-CV). Electrodes were held in place by 
stainless steel alligator clips, fastened into the well-plate lid with silicone sealant (Dow 
Corning 734) and used for external power-supply connection. 
 
 
Figure 3. Custom electrotaxis well system. (a) Schematic of electrotaxis channel 
construction. (b) Completely assemble electrotaxis well system. (c) Photo detail of 




Chambers were connected via agar-salt bridges (Figure 3d) to filter out potentially 
harmful electrode products. These bridges were comprised of 1/8” silicone tubing 
(McMaster-Carr 51135K11), filled with 5% autoclaved agar (BD Difco 214530), 1M 
KCl (VWR BDH0258), and 25 mM HEPES (Sigma, H4034). Polydimethylsiloxane 
(PDMS) “clips” were used to maintain tube curvature. Pre-fabricated tubes were stored in 
autoclaved deionized water with 100 mM KCl until use. 1/8” hole were drilled into the 
lid of the well-plate such that the bridges could be inserted to connect each electrolyte 
well to the nearest media reservoir.  
 The plating area was a channel constructed such that the height of the plating area 
was 202 µm high, 5 mm wide and 19 mm long. Walls of the plating area were built from 
two layers of double-sided solvent-resistant tape (polyethylene, McMaster-Carr 
7602A56), cut to fit the curvature of the well-plate and centered so that there was 
sufficient space for media reservoir on either end of the plating area channel. The plating 
area was topped by PDMS (Sylgard 184) strips, made to match the curvature of the well-
plate and cut to fit the width of the tape walls. These were made sufficiently high and 
sealed to the side of the well with autoclaved vacuum grease (Dow Corning, high-
vacuum silicone grease) such that the electrical current could only travel through the 
plating area channel when applied. COMSOL Multiphysics 4.4 was used to simulate 
current density in the channel using electrolyte conductivity of 1.5 S/m. 
2.2.3 Spot assays 
5,000 GFP+ cells in 2 µL of media were dropped as ‘spots’ (Figure 4) into the 
plating channel and allowed to attach for 15 minutes before addition of PDMS covers and 
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the rest of the media. Spots were allowed to grow for 24h before application of dcEF. 
Spots were imaged periodically during dcEF application and images were aligned over 
multiple time points in Adobe Photoshop using either registration marks made with 
solvent-resistant markers on the underside of the well, or by unique patterns in the tape 
edges that line the stimulation channel. Control wells received no dcEF. Images of spots 
were then intensity-thresholded to a binary mask, and summed across rows and fit to a 
single-term Gaussian model in Matlab (version R2012b, Mathworks) (Figure 4a). These 
fits were then segmented across time based on the initial timepoint fit for mean (µ0) into 
anodal and cathodal halves. The proportional change of cell area on the cathodal side 
minus the proportional change on the anodal side was defined as the cathodal shift 
(Figure 4b) used to express change in population shift over time relative to the alignment 




Figure 4. Spot assay analysis. (a) Thresholded, binary mask of GFP+ MatLyLu cells 
plated as a spot are summed across rows and then fit to a Gaussian curve. Scale: 200 µm. 
(b) Gaussian fits are then taken across time and segmented relative to the initial mean of 
the fit (µ0) and these proportional changes in summed cell area on either side are used to 
determine the amount of cathodal shift. 
 
2.2.4 Preparation of spheroidal cell aggregates 
A microwell-based method was used for producing spheroidal aggregates. PDMS 
reverse molds were made from Aggrewell 400Ex (StemCell Technologies 27840). These 
were used to cast 3% autoclaved Agar (BD Difco 214530) versions of the original 
Aggrewells. The agar versions were placed in 6-well plates and sterilized under ultra-
violet light before use. Cells were counted and diluted to either 700,000 or 1,400,000 
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cells per 3 mL—unless otherwise specified—and transferred in 3 mL volume to each 
well. Plates were centrifuged for 4 min at 280 x g and then transferred to 37ºC, 5% CO2 
and left for 24 hours to grow before experimental use.  
Aggregates were aspirated from the plates and added to electraxis channels with a 
1:1 ratio of aggregates/media to Growth-Factor-Reduced Matrigel (Corning #354230) in 
30 µL total volume (note: Matrigel batches were kept consistent within each set of 
experiments). The solution was allowed to solidify for 30 minutes before media 
reservoirs were filled. Cells were given 24h to acclimate to 3D conditions before 
application of electrical fields. 
2.2.5 Application of electrical fields 
Electrical fields were applied to each of the alligator clips on the electrotaxis 
chambers via a simple series circuit of 27 V battery supply, and a 1MΩ potentiometer. 
Current through the system was measured with a digital multi-meter, as the potentiometer 
was adjusted in order to provide the desired field strength as calculated by Ohm’s law in 
this form: 
𝐼!"# = 𝐸 ∗ 𝜎 ∗ 𝐴 
Where: E is the desired field strength (in V/m); σ is the conductivity of the media (in S/m; 
set to 1.5 S/m for all included studies); A is the cross-sectional area of the electrotaxis 
channel, orthogonal to the flow of current (in m); and Iset is the set current measured by 
the multimeter (in A). 
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During ongoing stimulation, periodic checks are made: (i) to ensure set currents 
have remained consistent (note: in this study, we kept currents within ranges that would 
indicate a ±20 V/m per 4h drift in field strength)—experiments that do not meet this 
criteria are excluded from further analysis; (ii) to reset Iset to desired value; (iii) to replace 
media if any visually-detectable (by phenol red) pH shift gradient has formed; and (iv) to 
replace salt-bridges. The determination of this check period duration is done by small 
pilot studies for each experiment and depends mainly on the amount of current applied.  
2.2.6 Microscopy 
Images in sections 2.2-2.3.6 were taken with a Zeiss Axiovert 200 using 
Microlucida (v2.50.2a, MBF Bioscience) and for sections 2.3.7-2.3.8 we used a Leica 
DMi8 with Leica Application Suite X tile scan. Plates were all aligned in the microscope 
such that the anodal side (direction toward positive battery terminus) is to the left of the 
image. Z plane focus was set to the middle depth of the channel.  
2.2.7 Single cell analysis 
Single cell experiments were imaged under temperature control for up to 4h. 
Images were analysis using the manual-tracking tool in ImageJ (FIJI). Displacement 
toward the cathode was calculated by taking the scalar projection (|A| cos θ) of each 
segment length (|A|) where θ is the angle between cell’s path vector (A) and the electrical 
field line aligned toward the cathode (y=0 for x>0). Displacement magnitudes are then 
normalized by the duration between the initial and final time points for each segment and 
reported as an average of all segments for a given cell. 
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2.2.8 Spheroidal analysis 
Tiled images of plating channels containing spheroidal aggregates were taking 
before and during each experiment. Tiled imaged were re-aligned across multiple time 
points in Adobe Photoshop using either registration marks made with solvent-resistant 
markers on the underside of the well, or by unique patterns in the tape edges that line the 
stimulation channel. Control wells received no dcEF. Individual aggregrates were 
selected from the tiled images and cropped for further analysis. A conservative frontier-
based method was used for determining the extent of each aggregrate (Figure 5) and 
demarcated for each of four directions relative to the alignment of the dcEF (Figure 5d). 
The absolute outward shift of each frontier over time is reported for each aggregate. 
Cathodal bias is defined as the outward shift of the cathodal frontier minus the outward 
shift of the anodal frontier. Similarly, the orthogonal bias is the outward shift of the 




Figure 5. Definition of frontier bounding boxes. Frontiers are defined using the 
maximal extent of each spheroidal aggregate (a & b) in one of four directions as defined 
in (d). The signed magnitude of outward change (c) in frontier from one time point to the 
next is used to report change in the aggregates. Scale: 100 µm. 
The bounding box formed from the frontiers is also used for reporting size of the 
aggregates as they change over time; these are normalized to the size of the initial frontier 
bounding box at time=0 and reported as a proportional change in area. Linear regressions 
of the initial aggregate area versus the cathodal bias were done with Prism 7 (Graphpad 
Inc.). 
2.2.9 Graphing and statistics 
All graphs and statistics analysis were done with Python (v2.7.x, Python Software 
Foundation, Anaconda Distribution) or Prism 7 (Graphpad Inc.) unless otherwise 
specified. The statistical methods used are reported for each result, in place. α=0.05 





2.3 Results & Discussion 
2.3.1 Electrotaxis chamber validation with MatLyLu cells 
Our newly designed electrotaxis chambers were first validated computationally, 
using COMSOL Multiphysics, to verify that a consistent current density would be 
applied within the plating channel (Figure 6a). Subsequently, we were able to reproduce 
previous results using the MatLyLu cell line that is known to electrotax toward a cathode 
[Djamgoz, 2001]. We were able to show results similar to those found in Djamgoz, et al., 
such that after 2h of exposure to a 100 V/m electrical field, MatLyLu cells moved over 
twice as much as unexposed cells. The control cells also had only a small net 
displacement (3.95±3.86 µm) compared to exposed cells that were significantly more 
attracted to the cathode (26.11±11.75 µm). Further, comparison of the net, field-
orthogonal displacement, which should not be affected by an electrical field, resulted in 




Figure 6. Validation of electrotaxis chamber wells. (a) COMSOL simulation of 
electrotaxis chamber wells with Iset = 330 µA. (b, c & d) MatLyLu single cell tracking 
results in electrotaxis chamber wells for single cells tracked over two hours for both no 
electrical field (CTL, n=20) and stimulation equivalent to 100 V/m (n=22) for: (b) 
displacement along the electrical field lines toward the cathode; (c) total path length 
traveled, regardless of directionality; and (d) displacement along the axis orthogonal to 
the electrical field. ****p < 0.0001 by Student’s t-test. 
 
2.3.2 U87mg cells have mixed electrotactic response at population densities 
Our first attempt to perform electrotaxis at population densities was to run spot 
assays as 2-dimensional models of tumor invasion using one of most widely studied 
GBM cell lines, U87mg. We hypothesized that electrotaxis would distort the radial 
outward growth from the initial spot in a way that would mirror a collective cell response 
to a signaling gradient. Over 48h our positive control MatLyLu spots developed a 
detectable difference in positive cathodal shift under dcEF, however, the U87mg cells did 
not exhibit a bias in directionality with the application of dcEF (Figure 7a).  Under 
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further inspection, we noticed that while the global Gaussian envelope did not bias over 
time for the dcEF+ U87mg spots, certain regions of the cell-area profile displayed 
marked shifts, locally. At later time points, the U87mg cells began to coalesce into 3D 
aggregates in both dcEF and control conditions when regions of the spot became over-
confluent. These 3D aggregates appeared to elicit a directional response toward the 
cathode in a dcEF (Figure 7c) whereas control aggregates had unbiased outward growth 
over time (Figure 7b). 
 
 
Figure 7. Spot assays undergoing electrotaxis. (a) Cathodal shift of GFP+ MatLyLu 
(MLL) or U87mg  (U87) cells exposed to 100 V/m dcEF (EF) of no dcEF (CTL) for 48h. 
Mean ± standard error of the mean (SEM) shown. (b & c) Detail of GFP+ U87mg spot 
assays were 3D aggregates have formed. Pseudocolored for time=0h (red) and time = 8h 
(green) for no dcEF (b) and 100 V/m (c). Scale: 400 µm. 
 
 
2.3.3 U87mg cells do not exhibit electrotaxis at single-cell densities 
We next performed a series of experiments in order to separate the 2D and 3D 
aggregate aspects of the spot assays. We first performed a series of single cell tracking 
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experiments with U87mg cells dispersed in 2D (Figure 8a) or embedded, but dispersed in 
3D matrigel (Figure 8b). We observed no electrotactic bias even with a 300 V/m field in 
2D.  This was surprising as it conflicts with what was previously seen for U87mg cells 
[Li, 2013], though Huang, et al., have also described similar null results with U87mg 
cells, noting that these cells did not elicit an electrotactic effect under dcEFs smaller than 
600 V/m. At the time, however, we wondered whether this was a result of cell plating 
density or interference of our particular serum additives. Thus we performed single-cell 
tracking experiments at 100 and 300 V/m altering the plating density in each spot and 
also using different media formulations (serum-free, 1% FBS, and 1:100 and 1:200 ratios 
of matrigel to complete media), yet none of these conditions had significant effect on 
electrotactic response (Figure 8c). Based on our experiments we conclude that in dcEF 




Figure 8. U87mg cells in single cell format do not exhibit electrotactic bias. U87mg 
cell were plated as dispersed 2D (a) or 3D (b) cells and exposed to dcEFs although 
exhibited no electrotactic bias relative to controls without dcEF. No statistically 
significant difference detected in (a) by One-way ANOVA with Holm-Sidak post-hoc 
test, nor in (b) by Student’s t-test. (c) Alterations in plating density (in 5 µL spots) or 
media formulation also did not elicit an electrotaxis effect. MatLyLu (MLL) single cell 
controls re-display from FIGURE 2.3.1 for direct comparison. No significant difference 
other than MLL 100 V/m relative to all other conditions by One-way ANOVA with 





2.3.4 U87mg spheroidal aggregates invade cathodally in dcEFs 
To further explore the electrotactic behavior that we observed in our over-
confluent spot assays, we used the Aggrewell method to plate isolated spheroidal 
aggregates in our electrotaxis wells. These aggregates, embedded in a 3D matrix of 
matrigel, matched the overall response of the aggregates in our spot assays, moving with 
a cathodal bias under dcEF exposure (Figure 9a,b). After only 8h a significant difference 
was detected in terms of both the cathodal frontier (for 250 V/m dcEF relative to control, 
p=0.0142) and the overall cathodal bias (for both 100 and 250 V/m dcEF conditions 
relative to control, p=0.0448 and p<0.0001 respectively) (Figure 9c) showing a mean 
cathodal bias of 68±16µm for 250 V/m, for 100 V/m, 37±20µm and 6±12µm for controls 
(mean±SEM). The cathodal bias for 100 V/m and 250 V/m were also found to be 
significantly different from each other (p = 0.0448). The anodal frontier was not 
significantly different, though the mean response did decrease with increased voltage. 
However, what the conservative bounding box method cannot capture is that the bulk of 
the aggregate has shifted while leaving behind trailing pseudopodia or immobile cells that 
are included when we demarcate frontiers. The proportional change in spheroid area, as 
indicated by the size of the frontier bounding box, was slightly, but significantly 
increased with 100 V/m dcEF (p=0.0242), but not discernably different for 250 V/m 
dcEF relative to control. Using 24h data from later experiments we also found that the 
initial spheroid area was not a significant factor (R2 = 0.00037, not different than slope of 




Figure 9. U87mg spheroidal aggregates exhibit cathodal electrotaxis. (a) GFP+ 
U87mg control aggregates showing no bias in growth direction after 8h. (b) GFP+ 
U87mg aggregates exposed to 250 V/m dcEF exhibiting cathodal bias, detectable within 
8h. (a & b) are pseudo-colored for time=0 (red), time =8h (green). (c) Quantitative 
assessment of the outward shift of aggregate frontiers after 8h. For cathodal frontier: 
*p=0.0142; for cathodal bias: *p=0.0448, ****p<0.0001; by Two-way ANOVA and 
Holm-Sidak post-hoc test.  Mean±SEM shown. (d) Proportional change in spheroid area 
from time=0 to time=8. *p=0.0242, with One-way ANOVA and Holm-Sidak post-hoc 
test. Mean±Tukey box plots shown. (e) Linear regression of initial spheroid area versus 
cathodal bias after 8h stimulation with 250 V/m dcEF. R2=0.00037, not different than 
slope of 0 with p=0.8879. Scale: 150µm. 
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2.3.5 DAOY spheroidal aggregates electrotax anodally in dcEFs 
We next applied the same spheroidal aggregate procedure to a commonly used 
cell line model of human MB, DAOY. After just 8h of 250 V/m dcEF exposure, these 
aggregates exhibited a significant (p<0.0001) difference in cathodal bias, yet unlike the 
U87mg cells, the movement was toward the anode (-69±12µm) relative to controls (-
9±8µm) (Figure 10a). For the DAOY aggregates, the outward movement of the anodal 
frontier (34±9µm) was larger, but not statistically different than in the controls (20±9µm), 
however the outward growth of the cathodal frontier was (-35±10µm relative to 11±5µm 
in controls). This suggests that there may be stronger sensing, or perhaps a repulsive 
effect, of the dcEF at the trailing end of the DAOY aggregates. The bulk of the cathodal 
bias in the U87mg aggregates came from the change in the cathodal frontier as well, but 
with a different polarity of response. Like the U87mg counterparts, the DAOY cells did 
not exhibit a proportional change in overall area (Figure 10b), nor did the initial spheroid 
area correlate with cathodal bias (Figure 10c).  
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Figure 10. DAOY spheroidal aggregates exhibit anodal electrotaxis. (a) Quantitative 
assessment of the outward shift of aggregate frontiers after 8h. **p=0.0032; 
****p<0.0001; by Two-way ANOVA and Holm-Sidak post-hoc test.  Mean±SEM 
shown. (b) Proportional change in spheroid area from time=0 to time=8. Not significant 
(p=0.1706) by One-way ANOVA and Holm-Sidak post-hoc test. Mean±Tukey box plots 
shown. (c) Linear regression of initial spheroid area versus cathodal bias after 8h 
stimulation with 250 V/m dcEF. R2=0.01167, not different than slope of 0 with p=0.5770. 
(d) Example spheroid morphology before and after experiment, with and without 250 
V/m dcEF. Scale: 200µm. 
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2.3.6 24h electrotaxis of additional GBM and MB spheroidal aggregates 
In addition to the U87mg and DAOY cell lines, we tested a few other GBM and 
MB models as spheroidal aggregates for their electrotactic responses. These experiments 
were done over 24h, rather than 8h and thus we have also provided 24h data for the 
U87mg and DAOY aggregates as well that were obtained during the experiments 
presented in Chapter 4 (Figure 11).  After 24h of dcEF there are some marked difference 
to our 8h stimulations. U87mg aggregates still show a significant difference in both 
cathodal frontier shift (p=0.0002) and cathodal bias (p<0.0001) relative to controls 
(Figure 11a). Though, the mean cathodal bias of the U87mg aggregates undergoing 
electrotaxis does not scale linearly with time from the 8h to 24h data (only 1.32x farther 
over 3x longer duration), it does increase to 90±14µm after 24h relative to controls -
6±20µm. The area of the U87mg aggregates is, after 24h, significantly larger than the 
control (p=0.0133) seen as an elongation parallel to the dcEF field lines (Figure 11c,e). 
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Figure 11. U87mg and DAOY spheroidal aggregates after 24h dcEF exposure. (a & 
b) Quantitative assessment of the outward shift of aggregate frontiers after 24h for (a) 
U87mg, and (b) DAOY spheroidal aggregates with 250 V/m dcEF (STIM) or no dcEF 
(CTL). **p=0.0032; ***p=0.002 for (a), p=0.0007 for (b); ****p<0.0001; by Two-way 
ANOVA and Holm-Sidak post-hoc test. Mean±SEM shown. (c & d) Example spheroid 
morphology before and after experiment, with and without 250 V/m dcEF for (c) U87mg, 
and (d) DAOY spheroidal aggregates. Scale: 200 µm. (e & f) Proportional change in 
spheroid area from time=0 to time=8 for (e) U87mg, and (f) DAOY spheroidal 
aggregates. *p=0.0133; ****p<0.0001; by One-way ANOVA and Holm-Sidak post-hoc 
test. Mean±Tukey box plots shown. 
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The DAOY aggregates, after 24h, again exhibit a significant difference in the 
cathodal frontier (p<0.0001) but not the anodal frontier, and maintain their anodal bias 
under dcEF (-81±8µm relative to 0±12µm in control, p<0.0001). For these cells, the 
cathodal bias is also greater than in the 8h case, though this is also less than would be 
expected for linear scaling over time (2.3x farther over 3x longer duration). One major 
difference to the 8h experiments is that the DAOY aggregrates now exhibit significant 
retraction in the orthogonal frontiers (p=0.0032 for orthogonal, p<0.0001 for 
orthogonal’), which results in a significantly smaller spheroidal area after 24h (p<0.0001) 
(Figure 11f). 
2.3.6.1 A172, LN229, T98G, and U373 GBM cell lines undergo anodal electrotaxis 
We tested the electrotactic response of four additional human GBM cell lines 
under a 250 V/m dcEF for 24h. To our surprise, all of these additional lines exhibited 
electrotaxis, but unlike the U87mg cells, bias was toward the anode. The matrigel batch 
used for these experiments was different than previous studies, although U87mg tandem 
controls still showed a cathodal response. 
The A172 cells (Figure 12) underwent electrotaxis similar to the DAOY cells, in 
that there was a significant decrease in outward growth on the cathodal edge (p=0.0005), 
but not the anodal. However, the A172 anodal bias (-181±34µm, mean±SEM), which was 
significantly greater in magnitude under 250 V/m dcEF than the controls (-22±17µm, 
p<0.0001), was double that seen for DAOY cells. A slight, but not statistically significant 
decrease in spheroidal area was observed, and again spheroid size was not significantly 
related to cathodal bias. 
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Figure 12. A172 aggregates undergo anodal electrotaxis. (a) Quantitative assessment 
of the outward shift of A172 aggregate frontiers after 24h. ***p=0.0005; ****p<0.0001; 
by Two-way ANOVA and Holm-Sidak post-hoc test.  Mean±SEM shown. (b) 
Proportional change in spheroid area from time=0 to time=24. Not significant (p=0.3351) 
by One-way ANOVA and Holm-Sidak post-hoc test. Mean±Tukey box plots shown. (c) 
Linear regression of initial spheroid area versus cathodal bias after 24h stimulation with 
250 V/m dcEF. R2=0.08628, not different than slope of 0 with p=0.5721. (d) Example 
A172 spheroid morphology before and after experiment, with and without 250 V/m 
dcEF. Scale: 200µm. 
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LN229 cells (Figure 13) also exhibited a strong anodal bias (-127±15µm, mean±SEM), 
significantly different than controls (-14±734µm, p<0.0001), and a significant decrease in 
cathodal frontier growth (p<0.0001). However, the LN229 aggregates also exhibited a 
significant increase in outward shift of the leading, anodal frontier (p-0.0074). The 
LN229 cells also exhibited a greater, but still not significant decrease in spheroid 
bounding box area, and showed weak correspondence between the cathodal bias and the 
initial spheroid area. 
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Figure 13. LN229 aggregates undergo anodal electrotaxis. (a) Quantitative assessment 
of the outward shift of LN229 aggregate frontiers after 24h. **p=0.0074; ****p<0.0001; 
by Two-way ANOVA and Holm-Sidak post-hoc test.  Mean±SEM shown. (b) 
Proportional change in spheroid area from time=0 to time=24. Not significant (p=0.0526) 
by One-way ANOVA and Holm-Sidak post-hoc test. Mean±Tukey box plots shown. (c) 
Linear regression of initial spheroid area versus cathodal bias after 24h stimulation with 
250 V/m dcEF. R2=0.002407, not different than slope of 0 with p=0.8736. (d) Example 
LN229 spheroid morphology before and after experiment, with and without 250 V/m 
dcEF. Scale: 200µm. 
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T98G aggregates (Figure 14) exhibited an even stronger anodal bias (-194±8 µm, 
p<0.0001 relative to controls with -36±11 µm), with the lowest variability of all tested 
lines. The T98G anodal frontiers were also significantly different than controls 
(p=0.0104), but the effect seen was not a greater growth than the maximum seen in 
controls, but more consistently maximal. This consistency also impacted the efficiency of 
the electrotactic response, as the whole spheroid moved together and displayed no 
significant change in bounding box area over time. 
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Figure 14. T98G aggregates undergo anodal electrotaxis. (a) Quantitative assessment 
of the outward shift of T98G aggregate frontiers after 24h. *p=0.0104; ****p<0.0001; by 
Two-way ANOVA and Holm-Sidak post-hoc test.  Mean±SEM shown. (b) Proportional 
change in spheroid area from time=0 to time=24. Not significant (p=0.6832) by One-way 
ANOVA and Holm-Sidak post-hoc test. Mean±Tukey box plots shown. (c) Linear 
regression of initial spheroid area versus cathodal bias after 24h stimulation with 250 
V/m dcEF. R2=0.1433, not different than slope of 0 with p=0.2509. (d) Example T98G 
spheroid morphology before and after experiment, with and without 250 V/m dcEF. 
Scale: 200µm. 
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The greatest anodal bias of all the lines tested was from the U373 aggregates (Figure 15) 
with -235±30 µm (mean±SEM) under 250 V/m compared to a mere -10±16 µm in 
controls (p<0.0001). The outwardly extending anodal and trailing cathodal frontiers were 
both significantly different than in controls (p<0.0001). Morphologically, these cells were 
also distinct in that processes on the trailing end did not merely retract, yet appear to 
wrap around the spheroid bulk toward the anode after 24h. These aggregates displayed no 
overall change in spheroid area over time, and although their cathodal bias was more 
strongly related to initial spheroid area, this was largely due to the small variability in 
cathodal bias relative to the magnitude, and the linear fit was not significantly different 
than a slope of 0. 
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Figure 15. U373 aggregates undergo anodal electrotaxis. (a) Quantitative assessment 
of the outward shift of U373 aggregate frontiers after 24h. ****p<0.0001; by Two-way 
ANOVA and Holm-Sidak post-hoc test.  Mean±SEM shown. (b) Proportional change in 
spheroid area from time=0 to time=24. Not significant (p=0.4068) by One-way ANOVA 
and Holm-Sidak post-hoc test. Mean±Tukey box plots shown. (c) Linear regression of 
initial spheroid area versus cathodal bias after 24h stimulation with 250 V/m dcEF. 
R2=0.2156, not different than slope of 0 with p=0.1283. (d) Example U373 spheroid 
morphology before and after experiment, with and without 250 V/m dcEF. Scale: 200µm. 
 40 
2.3.6.2 Electrotaxis of alternate MB cell lines 
Two other MB cell lines were also tested for their electrotactic responses, 
however, these results area herein presented with skepticism. Both the D283MED and 
D341MED cell lines were unable to be plated as spheroidal aggregates; these cell lines 
are suspension culture lines and do not form strong cell-cell adherence when plated as 
aggregates. We attempted to plate the D341MED cells directly as monoclonal spheroids, 
yet these cells readily disassociated into dispersed single-cell format during mixing with 
matrigel. Thus, these cells have been omitted from the current study, as it would require 
substantial additional time to grow the D341MED cells, in situ, in our electrotaxis 
chambers. 
We were able to obtain results from the D283MED line (Figure 16), which were 
plated as a mix of single cells and monoclonal spheroids, yet few of the spheroids 
survived the plating process. Nonetheless, we were able to detect a small but significant 
cathodal bias in these samples (22±12µm, mean±SEM, relative to 5±4µm in controls, 
p=0.0444), but two things warrant skepticism of this result: (i) effect was largely due to 2 
outlying replicates; and (ii) no invasive processes can be seen extending from the 
spheroids. It remains unclear why the outlier samples were seen to have a cathodal effect 
(one is shown in Figure 16d), and whether this was truly an electrotactic effect. 
Nevertheless, live-cell imaging is likely required to further understand how these cells are 





Figure 16. D283Med spheroids undergo cathodal electrotaxis, although not 
consistently. (a) Quantitative assessment of the outward shift of D283Med spheroid 
frontiers after 24h. *p<0.0444; by Two-way ANOVA and Holm-Sidak post-hoc test.  
Mean±SEM shown. (b) Proportional change in spheroid area from time=0 to time=24. 
Not significant (p=0.1414) by One-way ANOVA and Holm-Sidak post-hoc test. 
Mean±Tukey box plots shown. (c) Linear regression of initial spheroid area versus 
cathodal bias after 24h stimulation with 250 V/m dcEF. R2=0.02792, not different than 
slope of 0 with p=0.6925. (d) Example D283Med spheroid morphology before and after 
experiment, with and without 250 V/m dcEF. Scale: 200µm. 
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2.4 Conclusion 
In this chapter, we have described the design of our flexible in vitro electrotaxis 
system and validated it against a known electrotaxis model (MatLyLu cells). This system 
can be used as complement to existing electrotaxis setups, with emphasis on higher cell 
densities, populations in 3D, and for longer-term experiments—especially those where 
live-cell microscopy may not be available, or where microfluidic fabrication is 
inaccessible (or not cost-effective). 
U87mg and DAOY cell lines were initially explored for their electrotactic 
responses. U87mg cells, in particular, led to the interesting finding that while they did not 
electrotax in 2D or diffusely in 3D—they did however electrotax when aggregated into 
3D cell clusters. While we did not follow this aspect further in the current study, it acts as 
yet another piece of evidence that our go-to 2D in vitro setups are, perhaps obviously, 
inadequate to capture and recapitulate the full gamut of cellular responses undergoing 
electrotaxis.  
We continued this study by testing other GBM and MB cell lines, with limited 
success for the MB cells. Surprisingly, all additional GBM cell lines moved in the 
opposite direction from the U87mg cells, and up to twice as fast (Figure 17). U87mg cells 
are generally considered one of the least invasive GBM cell line models, and thus this 
could be an array of responses similar to what was seen previously in breast and prostate 
cancer lines, with the metastatic potential correlating to stronger responses, and 




Figure 17. Comparison of electrotactic biases for GBM and MB cell lines. 
 
Regardless, our findings suggest that there remains no guarantee, that given a 
particular tissue type, the cells will have similar directional preference in response to the 
same physio-chemical signals. In the following chapters we begin to investigate the 
question of why this is the case for U87mg and DAOY cells, by looking at a broad screen 
of potential mechanistic signaling patterns with the hope that a better understanding of 
cell-line-specific expression patterns could advance our understanding of how to predict, 
or control, an electrotactic response. 
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CHAPTER 3. TRANSCRIPTOMIC ANALYSIS OF U87MG 
GLIOBLASTOMA AND DAOY MEDULLOBLASTOMA 
SPHEROIDAL AGGREGATES UNDERGOING ELECTROTAXIS 
 
3.1 Introduction 
Directed cell migration and the mechanisms that underlie its processes are complex, 
multimodal, and often cell-specific—electrotaxis is no different. The mechanisms that 
have been studied or found to be in some way involved in electrotaxis have ranged from 
alternatively-spliced channel expression [Fraser, 2005], inositol-phospholipid signalling 
[Zhao, 2006], growth-factor receptor electro-polarization [Yan, 2009], purinergic 
receptors [Riding, 2015], lipid rafts [Lin, 2017], and glycocalyx bending [Hart, 2017]. 
While there exist many studies focused on a small number of or single targets,  few 
broad signaling scans on cells undergoing electrotaxis have been performed. In their 
study of lung cancer electrotaxis, Huang, et al., ran microarray analyses finding 431 gene 
probes (out of 54,675) to be significantly different after dcEF application, with the most 
significantly represented signaling pathways being those for adherens and tight junctions, 
and hTerc transcriptional regulation [Huang, 2011]. Li, et al., included a 60-protein 
phosphorylation antibody array in their study, which had directed them to their 
consequent inquiry into dcEF-mediated effects on the ERK pathway [Li, 2013]. Barcoded 
Dictyostelium mutants have also been used as a high-throughput method to piece apart 
electrotaxis mechanisms, through conservation of genes that correlate with electrotaxis 
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hyperresponsitivity [Gao, 2015]. Two recent studies have included ribonucleic acid 
sequencing (RNA-SEQ) in their mechanistic analysis of electrotaxis, providing insights 
into how dcEFs impact actin cytoskeletal, mitogen-activated protein kinase (MAPK), and 
focal adhesion signaling [Yao, 2015; Li, 2015]. Though, even with these myriad 
electrotaxis mechanism studies, there is still no general consensus on how a dcEF is 
sensed, how an electrotactic direction is determined, nor how the directional persistence 
is maintained.  
In this chapter, we continue the effort to explore, discover, and explain the effects 
of dcEFs on cellular signaling. Due to the wide gamut of purported mechanisms, we too 
chose to screen broadly, looking at the molecular profile of U87mg and DAOY cells—
two of our cell lines tested previously that exhibited opposing electrotactic responses. In 
this chapter we describe our use of microfluidic quantitative, reverse transcription 
polymerase chain reaction (qRT-PCR) and RNA-SEQ to study underlying signaling 
impacts of dcEF exposure and electrotaxis. 
3.2 Materials & Methods 
3.2.1 in vitro cell culture and cell lines 
U87mg (human glioblastoma, ATCC HTB-14), and DAOY (human 
medulloblastoma, ATCC HTB-186) cells were obtained from ATCC. All cells were 
maintained at 37ºC with 5% CO2 in Dulbecco’s Modified Eagle Medium (Cellgro 15-
017CV) with 10% fetal bovine serum (Gemini 900-108), 1% L-Glutamine (Lonza 17-
605F), 1% Non-essential amino acids (Cellgro 25-025-CI), and 1% penicillin-
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streptomycin (Corning 30-001-CI).  Cells were passaged before confluence using 0.25% 
Trypsin-EDTA (gibco 25200-056). 
3.2.2 qRT-PCR 
3.2.2.1 Cell culture and preparation 
U87mg and DAOY spheroidal aggregates were formed using 700,000 cells in 
3mL per agar aggrewell. Aggrewells were incubated for 24h and then spheroids were 
transferred to electrotaxis chamber and embedded in 1:1 cell culture medium to reduced-
growth-factor Matrigel (Corning 354230) and allow to acclimate for 24h before 
stimulation. Cells were stimulated at 250 V/m for 0, 2, or 8h. Electrotaxis channels were 
scraped and the cells and Matrigel collected into 600 µL of cell recovery solution (BD, 
now Corning 354253) and kept on ice for 30 min. Paired duplicate samples were pooled 
together, providing 4 biological replicates for each condition (except 8h DAOY which 
only had n=3, due to poor RNA quality in one sample). Pools were centrifuged for 5 min 
at 800xg and resuspended in 75 µL 1% ß-mercaptoethanol (Sigma M3148)/Buffer RLT 
(Qiagen 79216), vortexed for 1 min, and stored at -80ºC. 
3.2.2.2 RNA Isolation and quality control 
RNA was isolated using an RNeasy Micro Kit (Qiagen 74004). Sample purity and 





Electrotaxis candidate gene assay primers (100 uM) (Table 1) were obtained from 
Fluidigm. Primers and sequences are listed in Appendix A (Table 7). For this assay, 
ACTB, GAPDH, IPO8, RPL13A, SDHA, and TBP were used as housekeeping genes 
[Kreth, 2010]. For the migration gene assay, a Fluidigm-format Human Motility Array 
(SABiosciences PAHS-128ZH-1, 20uM) was used. Sabioscience primer sequences are 
proprietary, however, the genes tested are listed in Table 2 and in Appendix A (Table 8). 
For this assay, ACTB, B2M, GAPDH, HPRT1, and RPL13A were provided on the array 
as housekeeping genes. 
 
Table 1. Candidate genes for investigation of electrotaxis mechanisms 
GENE Purported role in electrotaxis Reference(s) 
AKT1 PI3K/AKT mediated response in neural progenitor cells Meng, 2011 
CCL2 Increased gene expression in human dermal fibroblasts under dcEF Park, 2015  
CDC42 
Hypothesized controller of cell polarity; Increased activity in glioma 
under dcEFs; Overexpressed in cathodal end of cathodal growing 
growth cone (xenopus) under dcEF 
Etienne-Manneville, 
2003; Li, 2013; 
Rajnicek, 2006 
EGFR 
Part of PI3K/AKT mediated response in NPCs; EGFR dependence 
of lung adenocarcinoma cells; Increased gene expression in human 
dermal fibroblasts under dcEF 
Meng, 2011; Tsai, 
2013; Park, 2015 
FGF2 Increased gene expression in human dermal fibroblasts under dcEF Park, 2015  
FLT1 Up-regulated angiogenic factor in endothelial cells Bai, 2011 
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Table 1 (continued) 
FRK Hypothesized down-regulation corresponding with increased invasion Shi, 2015 
FYN Src family, hypothesized as potential migration regulator Han, 2014 
IPCEF1 Part of PI3K/AKT mediated response in neural progenitor cells Meng, 2011 
MAPK1 Increased gene expression in human dermal fibroblasts under dcEF Park, 2015  
MAPK14 (p38) Up-regulated in glioma under dcEF Li, 2013 
MAPK3 Increased gene expression in human dermal fibroblasts under dcEF Park, 2015 
MAPK8 (Janus Kinase) Up-regulated in glioma under dcEF Li, 2013  
MMP1 Hypothesized to be downstream response of dcEF induction on EGFR Anand, 2011 
MMP9 Down-regulated in human dermal fibroblasts under dcEF Park, 2015  
PIK3CA Part of PI3K/AKT mediated response in neural progenitor cells Meng, 2011 
PRKACA Hypothesized indicator of dcEF-induced cAMP activity Pullar, 2005 
PRKCA Hypothesized indicator of dcEF-induced cAMP activity Pullar, 2005 
PTEN Part of PI3K/AKT mediated response in neural progenitor cells; Down-regulated in schwann cell electrotaxis 
Meng, 2011; Yao, 
2015 
RAC1 
Necessary for keratinocyte electrotaxis; Part of NMDAR signaling 
pathway in electrotaxis of neural stem/progenitor cells; Increased 
activity in glioma under dcEFs; Overexpressed in cathodal end of 
cathodal growing growth cone (xenopus) under dcEFs 
Pullar, 2006; Li, 
2008; Li, 2013; 
Rajnicek, 2006 
RHOA Overexpressed in anodal end of cathodal growing growth cone (xenopus) under dcEFs Rajnicek, 2006 
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Table 1 (continued) 
SCN1B Hypothesized indicator of voltage-gated sodium channel activity Yildirim, 2012 
SGK1 Hypothesized to indicate dcEF-induced ion channel activity or stress response Lang, 2013 
SOD2 Increased expression in glioma under dcEFs Li, 2013  
VEGFC Hypothesized paracrine signal, mirroring glial precursor growth Kranich, 2009 
 
Table 2. Human Motility PCR Array genes grouped by functional category. 
FUNCTION GENES 
Chemotaxis FGF2, ITGB2, MAPK1, MYH10, MYH9, PLAUR, PLD1, 
PRKCA, RAC2, TGFB1, VEGFA, WASF2, WIPF1 
Receptors EGFR, IGF1R, ITGA4, ITGB1, ITGB2, ITGB3, MET, 
PLAUR, RHO 
Growth Factors CSF1, EGF, FGF2, HGF, IGF1, TGFB1, VEGFA 
Rho Signaling ACTR2, ACTR3, ARHGDIA, LIMK1, MSN, MYL9, 
MYLK, PLCG1, PLD1, PRKCA, PTEN, PTPN1, RHO, 
RHOA, RHOB, RHOC, RND3, ROCK1, VIM 
Rac Signaling ACTR2, ACTR3, BAIAP2, CFL1, CRK, PAK1, PAK4, 
PLD1, PRKCA, RAC1, RAC2, STAT3, WASF1, WASF2, 
WAS 
CDC42 Signaling ACTR2, ACTR3, CDC42, PFN1, WASF1, WASF2, 
WASL 
Cell-Cell Adhesion DPP4, EGFR, EZR, ITGA4, ITGB1, ITGB2, MSN, 
MYH9, ROCK1, TGFB1 
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Table 2 (continued) 
Cell-Matrix Adhesion ACTN1, ACTN3, CSF1 (MCSF), ILK, ITGB1, ITGB2, 
ITGB3, MMP14, PTEN, PTK2B, PXN, RASA1, RHOA 
Focal Adhesion ACTN1, ACTN3, ARHGEF7, BCAR1, CAPN1, CAPN2, 
CAV1, ENAH, ILK, ITGB1, MYL9, PTK2, PTK2B, PXN, 
TLN1, VASP, VCL 
Leukocyte Adhesion 
& Rolling 
EZR, ITGA4, ITGB1, ITGB2, MSN, ROCK1 
Integrin-Mediated 
Signaling 
BCAR1, ILK, ITGA4, ITGB1, ITGB2, ITGB3, MYH9, 
PTK2 
Filopodia BAIAP2, CDC42, DIAPH1, EGFR, ENAH, EZR, MSN, 
RDX, SVIL, VASP 
Lammelipodia CTTN, DPP4, EGFR, ENAH, FAP, PIK3CA, PLD1, 
PTK2, PXN, RDX, SVIL, VASP, VCL, WASF1, WASF2, 
WASL 
Stress Fibers ACTN4, DIAPH1, MYH10, MYH9, RHOA, RHOB, 
RHOC 
Membrane Blebs ACTN1, ACTN3, ACTN4, EZR, MYH10, MYH9, MYLK, 
RND3, ROCK1 
Invasive Projections ACTR2, ACTR3, ARF6, CDC42, CFL1, CTTN, DPP4, 
EGF, EZR, FAP, MMP14, MMP2, MMP9, MSN, MYH9, 
PLAUR, RAC2, RASA1, SH3PXD2A, SRC, SVIL, 
TGFB1, VEGFA, WASL, WIPF1 
Growth Cones ARHGEF7, CDC42, CFL1, PTK2B 
Membrane Ruffles ACTR2, ACTR3, ARF6, BAIAP2, BCAR1, CTTN, 
DIAPH1, EZR, ITGB1, MYH9, RAC1, RAC2, RDX, 
RHOA, TLN1, WASF2 
Cell Polarity CDC42, CFL1, EZR, IGF1R, ILK, MYH9 
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Table 2 (continued) 
Proteolysis AKT1, CAPN1, CAPN2, DPP4, FAP, HGF, MMP14, 
MMP2, MMP9, MYH9, PLAUR, TIMP2 
 
 
3.2.2.4 Library Preparation and Fluidigm qRT-PCR 
Complementary deoxyribonulcleic acid was produced slightly differently for each 
assay. For the candidate gene assay a RT2 First Strand kit (Qiagen 330401) was used; for 
the motility gene assay the RT2 Microfluidics Reagent System (Qiagen 330431) and RT2 
PreAMP Pathway Primer Mix for Fluidigm (Qiagen 330241) were used. Fluidigm qRT-
PCR was performed on a Fluidigm BioMark Genetic Analysis Platform at the Georgia 
Tech Genomics Core. 
3.2.2.5 Data Analysis 
qRT-PCR data were analyzed using the SABiosciences RT2 Profiler PCR Array 
Data Analysis web tool (version 3.5), with default settings other than a geometric mean 
used for housekeeping gene normalization and a cycle threshold of 35. Data were post-
processed and visualized using custom Python (v2.7.x, Python Software Foundation, 
Anaconda Distribution) code. Multiple hypothesis correction was done with the 





3.2.3.1 Cell Culture and Preparation 
U87mg and DAOY spheroidal aggregates were formed using 700,000 cells in 
3mL per agar aggrewell. Aggrewells were incubated for 24h and then spheroids were 
transferred to electrotaxis chamber and embedded in 1:1 cell culture medium to Growth 
Factor Reduced Matrigel (Corning 354230) and allow to acclimate for 24h before 
stimulation. Cells were stimulated at 250 V/m for 0, 2, or 8h. Electrotaxis channels were 
scraped and the cells and Matrigel collected into 600 µL of cell recovery solution (BD, 
now Corning 354253) and kept on ice for 30 min. Paired triplicate samples were pooled 
together, providing 4 biological replicates for each condition (except 8h DAOY which 
only had n=3, due to poor RNA quality in one sample). Pools were centrifuged for 5 min 
at 800xg, supernatant removed and stored at -80ºC. 
3.2.3.2 RNA isolation, Quality Control and Library Preparation 
RNA was extracted using a RNeasy Micro Plus Kit (Qiagen 74034). Purity and 
yield was assessed on a Nanodrop 2000 (Thermo-Fisher). RNA integrity was assessed 
with an Agilent Bioanalyzer RNA 6000 Nanokit on an Agilent Bioanalyzer 2100. The 3 
biological replicates with the best quality control results were chosen for each of the 6 
conditions. Library preparation was done with a TruSeq Stranded mRNA Sample 
Preparation Guide LT with polyA tail pull-down. Library was validated with an Agilent 
DNA 1000 kit after fragmentation and addition of adapters. Samples were cleaned with 
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AMPure XP beads and normalized with fluorimetric quantification to 10nM using a 
Qubit 2.0 Fluorometer using Qubit Broad Range (ThermoFisher Q32850) and High 
Sensitivity (ThermoFisher Q32854) kits.  
3.2.3.3 Sequencing 
The 3 samples for each condition with the best quality control analysis were 
selected for sequencing. RNA-Sequencing was performed by the High-Throughput DNA 
Sequencing Core Facility at Georgia Tech. Samples were run on an Illumina HiSeq 2500 
with single-ended, 100 base-pair reads using a cBOT to split lanes before sequencing.  
3.2.4 RNA-SEQ Data Analysis 
3.2.4.1 Post-Sequencing Quality Control 
Data were processed using the FASTQC Toolkit (v2.0.0, Illumina Basespace). 
Minimum read length was set to 32. Adapter, base, quality, and Poly-A/T trimming were 
performed according to previously published methods [McManes, 2014; Del Fabbro, 
2013; Hansen, 2010]. 
3.2.4.2 Sequence alignment and differential expression 
Transcript-level sequence alignment was done using the pseudo-alignment tool, 
Kallisto (0.43.0) [Bray, 2016] and the GENCODE v24 transcriptome for Homo sapiens 
(www.gencodegenes.org) [Harrow, 2012] using 100 bootstrap samples, single-end mode, 
with the average fragment length and standard deviation obtain for each sample during 
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quality control. Differential expression was performed using Sleuth [Pimentel, 2017] in R 
(v 3.2.1, R Foundation for Statistical Computing). 
3.2.4.3 Pathway over-representation analysis 
The differentially expressed transcripts were pre-filtered to exclude transcripts 
with an absolute fold change of less than 2-fold. For each condition-pair, gene ontology 
was performed using g:profiler version: r1732_e89_eg36 (http://biit.cs.ut.ee/gprofiler) 
[Reimand, 2016]. The Homo sapiens dataset was used and the search included Gene 
Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), CORUM, Reactome, 
and Regulatory Motif databases and the built-in g:SCS threshold was used to correct p-
values for significance cutoff. Default settings were used. QuickGo 
(https://www.ebi.ac.uk/QuickGO) web service was used for obtaining additional gene 
ontology information for visualization with Python (v2.7.x, Python Software Foundation, 
Anaconda Distribution). 
3.2.4.4 Pathway Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) (v3.0 build: 0160, 
http://www.broadinstitute.org/gsea) [Subramanian, 2005] was used to perform pathway 
enrichment analysis. Pre-ranked analysis was performed against the Molecular Signatures 
Database gene sets for: curated data (c2.all.v6.0), gene ontology (c5.all.v6.0), and 
oncogenic signatures (c6.all.v6.0) gene sets. For the ranking scheme, we used the 
negative-log of the multiple-hypothesis-corrected p-value (obtained via differential 
expression analysis in Sleuth) and signed according to the fold-change direction. The 
transcript with the lowest p-value was selected in cases of gene symbol collision. Default 
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settings were used except the maximum and minimum pathway size exclusion criteria 
were set to 1,000 and 5, respectively. 
3.2.5 Graphing and Statistics 
All graphs and statistics analysis were done with Python (v2.7.x, Python Software 
Foundation, Anaconda Distribution) or Prism 7 (Graphpad Inc.) unless otherwise 
specified. The statistical methods used are reported for each result, in place. 
 
3.3 Results & Discussion 
3.3.1 qRT-PCR: canonical motility & candidate gene arrays 
Our exploration of electrotaxis mechanisms began with a series of qRT-PCR gene arrays. 
The first was a custom gene array comprised of 25 genes either previously shown or 
hypothesized to involved in electrotactic machinery (Table 1). Gene expression was 
compared at 2h and 8h, relative to unstimulated cells, with significant, differential 
expression criteria set to p<0.05 and Log2(fold-change) of greater than 1 or less than -1 
(Figure 18). For these conditions, however, no genes were found to be significantly 
differentially expression, even before multiple hypothesis corrections to the p-values. 
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Figure 18. Candidate gene qRT-PCR volcano plots. (a & b) U87mg, or (c & d) DAOY 
cells were analyzed for gene expression of 25 candidate electrotaxis genes. Shown are the 
p-values and fold-changes for these genes comparing the expression at (a & c) 2h, or (b 
& d) 8h after dcEF onset, relative to controls at 0h without dcEF. Significance was 
determined as any gene with p<0.05 and a Log2(fold-change) of greater than 1 or less 





Next, deciding to expand our search to canonical mechanisms of cell movement, we 
analyzed gene expression using a commercial PCR array of known human motility genes 
(Table 2 and Figure 19). PLCG1 and RHOA (both involved in Rho signaling) were found 
to be differentially down-regulated in U87mg cells after 2h and EGF was observed to be 
up-regulated after 8h. The RHO receptor was the only gene found to be differentially 
expressed in DAOY cells, up-regulated after 8h. However, after multiple-hypothesis 
correction was performed on the initial p-values, none of those genes were found to 
remain significantly, differentially expressed. 
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Figure 19. Motility gene array qRT-PCR volcano plots. (a & b) U87mg, or (c & d) 
DAOY cells were analyzed for gene expression of 25 candidate electrotaxis genes. 
Shown are the p-values and fold-changes for these genes comparing the expression at (a 
& c) 2h, or (b & d) 8h after dcEF onset, relative to controls at 0h without dcEF. 
Significance was determined as any gene with p<0.05 and a Log2(fold-change) of greater 
than 1 or less than -1. While PLCG1, RHOA, RHO and EGF were found to be 
differentially-expressed under these criteria, after multiple-hypothesis correction was 





Initially, it was surprising to see no canonical motility genes differentially 
expressed under dcEF, when a dramatic change in motility behavior was clearly 
observed. However, what is distinct about our specific electrotaxis assay, is that the cells 
are embedded in a rich, adhesive matrix, and even without dcEF, the cells are invading 
directionally—away from the center of the cellular aggregate. What this means is that 
more so than previous electrotaxis assays—where cells have gone from random or non-
motile behaviors—our assays must be considered as moving from one form of directed 
invasion to another. Thus the dynamics of gene expression are likely more subtle, as they 
will relate more to the change in a particular cue, than a complete change in machinery 
for a different mode of invasion. Thus, we continued our study with a more powerful 
mRNA analysis tool in order to probe this subtlety. 
3.3.2 RNA-SEQ 
We performed RNA-SEQ on U87mg and DAOY spheroidal aggregates 0h, 2h, 
and 8h after being exposed to 250 V/m dcEFs. Over 91% of all transcript reads were 
pseudo-aligned and assigned to 145,327 unique transcript accessions (Appendix B, 
Figure 39). A number of these transcripts were found to be differentially expressed 
comparing either the 2h or 8h transcripts against the control, 0h transcripts. Differential 
expression was based on cutoff criteria of a false-discovery rate (FDR) < 0.05 and a 
Log2(fold-change) > 1 or < -1. Both the 8h conditions had substantially more 
differentially expressed transcripts as was to be expected, and the DAOY 8h comparison 
yielded 4.5x as many as the U87mg 8h comparison (Table 3 and Figure 20). Over 75% of 
all differentially expressed transcripts were for protein coding mRNA and the remaining 
were ‘processed transcripts’ (transcripts without an open reading frame) or ‘retained 
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introns’, mapping to purported splicing variant transcripts. Heatmaps and clustermaps of 
the most significantly differentially expressed genes are provided in Appendix B (Figure 
40, Figure 41, and Figure 42). 
 
Table 3. Counts for differentially expressed transcripts 
 U87 DAOY 
# Differentially Expressed Transcripts 2h 8h 2h 8h 
Up-regulated 4 25 6 155 
Down-regulated 9 39 1 137 




Figure 20. Differential expression of transcripts from RNA-SEQ. (a, b, c, & d) 
Volcano plots comparing fold-change and p-value of each identified transcript accession 
for (a & b) U87mg and (c & d) DAOY cellular aggregates for samples exposed to 250 
V/m dcEFs for (a & c) 2h, or (b & d) 8h compared 0h, unexposed controls. Significance 
threshold is set to FDR < 0.05 and a Log2(fold-change) of > 1 or < -1. Differentially 
expressed transcripts are shown in red. (e) Proportional breakdown of which GENCODE 
biotypes were associated to the identified, differentially expressed transcripts for each 
condition (U=U87mg, D=DAOY). 
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3.3.2.1 Over-representation analysis 
Using the differentially-expressed transcripts, we performed a pathway over-
representation analysis, finding several such over-represented pathways for all conditions 
except for the U87mg 2h set (Table 4). For the DAOY 2h condition, only CYR61 and 
TGFBR2 were found in any pathway annotations, so the pathways discovered for this 
search are likely unreliable for the current study: atrioventricular valve development & 
morphogenesis, and TGFB-receptor type II homodimer complex. Selected pathways from 
this analysis are listed in  Appendix B (Table 9, and Table 10). Both the U87 8h and 
DAOY 8h conditions yielded significant over-representation for mRNA metabolism, and 
gene expression regulation. A substantial number of transcription factors were also 
identified as being significantly overrepresented (Appendix B, Table 11). Additionally, 
the pathways for establishment of RNA localization, cell stress, and mRNA splicing via 
spliceosome were overrepresented in DAOY 8h genes. mRNA localization, for ß-actin in 
particular, has been previous implicated as a factor in directed cell migration 
[Shestakova, 2001]. Additionally, ATPase regulator activity was significantly 
overrepresented in U87 8h genes, which was previously shown to occur in tandem with 
ß-actin localization at the leading edge in electrotaxing calvarial osteoblasts [Özkucur, 
2011]. However, further analysis would be required to determine which, if any, mRNA 





Table 4. Counts for over-represented pathways by condition 
 U87mg DAOY 
 2h 8h 2h 8h 
# of significantly over-represented pathways 0 94 3 217 
 
Genes that were found to be differentially expressed after 8h for both U87mg and 
DAOY were well correlated to each other, with a Pearson’s correlation coefficient of 
0.9397 (p<7.9x10-19) (Figure 21). 5 pathways were found to be significantly over-
represented using this gene subset: RNA splicing, gene expression, RNA metabolic 
process, and two transcription factor pathways, ETV7 and E2F1 (Appendix B, Table 12). 
This suggests that if there is indeed a conserved transcriptional machinery in response to 




Figure 21. Correlation of transcripts differentially expressing in U87mg and DAOY. 
(a) Scatterplot of all transcripts that were differentially expressed after 8h dcEF for both 
U87mg and DAOY cellular aggregates. (b) List of gene symbols for based whether they 
were significantly up-regulated, or down-regulated for both U87mg and DAOY after 8h 
dcEF. No genes were found that fell outside these two sets. 
 
We also explored transcripts that were differentially expressed, but not for both 
cell types, and that had opposite directions of regulation across the two cell types (Figure 
22). These genes were of interest as candidates for describing the difference in directional 
preference between the cathodally-directed U87mg and anodally-directed DAOY cells, 
though no pathways were found that were significantly overrepresented by either subset 
of these genes (quadrants II and IV in Figure 22). 
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Figure 22. Correspondence of transcripts differentially expressed in U87mg and 
DAOY. (a) Scatterplot of all transcripts that were differentially expressed after 8h dcEF 
for both U87mg and DAOY cellular aggregates. (b) List of gene symbols for based 
whether they were significantly up-regulated, or down-regulated for both U87mg and 
DAOY after 8h dcEF. No genes were found that fell outside these two sets. 
 
3.3.2.2 Gene-set enrichment analysis 
We next performed a gene-set enrichment analysis using all transcripts with 
custom ranking: transcripts were ordered by the -Log-transformed p-values with the sign 
corresponding to the direction of their fold-change applied. Three of the msigDB gene 
sets were used, CURATED, GENE ONTOLOGY (GO), and ONCOGENIC, and the 
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number of significantly enriched gene sets for each are provided in Table 5. Significance 
criteria was p-value<0.05 and the GSEA tool recommended false-discovery rate of 0.25. 
Table 5. Gene-set enrichment analysis summary counts. 
 
D2 D8 U2 U8 
CURATED 872 1028 720 753 
GO 168 153 248 539 
ONCOGENIC 25 20 28 30 
     TOTAL 1065 1201 996 1322 
 
While there is not sufficient space in this thesis to present all of the significantly 
enriched gene sets, we have culled the lists for pathways we hypothesize, or have been 
previously shown, to be relevant to electrotaxis machinery. We found only limited 
pathways that matched the 2 previous RNA-SEQ studies for electrotaxis, which could be 
due to our cells being in 3D or plated as spheroids in invasion-promoting matrix. Li, et al. 
had found the broad cytokine-cytokine receptor and chemokine signaling pathways to be 
differentially regulated, however, neither of these were found enriched for any of our 
conditions [Li, 2015]. KEGG focal adhesion and MAPK signaling pathways were found 
to be upregulated, but only in DAOY cells, yet this matching the findings of Yao, et al. 
for Schwann cell electrotaxis toward the anode [Yao, 2015]. 
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Several signatures of chemotaxis were also present. Most strikingly, all conditions 
showed upregulation of genes matching data from Mili, et al., a study that characterized 
RNAs that were localized to cell protrusions under chemotaxis and haptotaxis [Mili, 
2008]. The gene ontology for RNA localization was also significantly enriched for all 
dcEF conditions.  
There were also many pathways enriched relating to the phosphoinositide 3-
kinase (PI3K) pathway, a pathway highly involved in chemotaxis intracellular regulation 
and previously shown to be a mediated of neural progenitor cell electrotaxis [Meng, 
2011]. Related pathways include the reactome PI3K cascade in both U87mg and DAOY 
cells after dcEF exposure, and gene ontology for phosphatidylinositol (3,4,5)-
triphosphate in DAOY cells. Mechanistic target of rapamycin (mTOR) genes were also 
enriched, as pathways for rapamycin sensitive genes, mTOR signaling and the Insulin-
like growth factor 1 (IGF1)/mTOR pathways were enriched in both cell lines. 
Several growth-factor-associated pathways were also upregulated for both cells 
including reactome pathways for EGFR, fibroblast growth factor receptor, Insulin 
receptor, transforming growth factor Beta (TGFB), and nerve growth factor, and the 
pathway interaction database pathways for MET, platelet-derived growth factor Beta, 
TGFB receptor, and vascular endothelial growth factor 1 and 2. All conditions also 
displayed positive enrichment for genes that had been previously found to be co-
regulated by hepatocyte growth factor (HGF) and Ki-Ras oncogene activity [Seiden, 
2006] 
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ErbB and EGFR signaling were also well represented by the significantly 
enriched gene sets. Both DAOY and U87mg cells under dcEFs were enriched for the 
gene ontology for regulation of ErbB signaling as well as the pathway interaction 
database ErbB1 downstream gene set. Enriched genes for both DAOY and U87mg cells 
under dcEFs also reflected data for genes affected by ErbB ligands, EGF & neuregulin 1 
[Nagashima, 2007]. 
Matching the over-representation analysis, both DAOY and U87mg 8h conditions 
were enriched for ATPase activator and regulator activity, as well as numerous pathways 
relating to spliceosome including the gene ontologies for regulation of mRNA splicing 
and prespliceosome, as well as the KEGG pathway for the spliceosome. 
3.4 Conclusion 
Mechanistic literature on electrotaxis has been limited in scope and largely 
contradictory when comparing between different cells. Single target methods, such as 
antibodies or inhibitors, have often been used, but are difficult to scale to screen the 
multitude of pathways involved in electrotactic processes—complex processes such as 
extracellular sensing and transduction, or cell polarity, motility, and persistent invasion. 
Scouring the underlying signaling pathways with omic-level analysis may be a better way 
to initially characterize a cell’s response, but has been relatively unused for electrotaxis 
studies. Further, causal effects of dcEFs on cells can be simultaneously explored when 
performed omic analyses, as the procurement of transcripts from a bulk cell does not 
discriminate to only those signals involved in electrotaxis. 
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Our initial high-throughput qRT-PCR custom screens elicited no findings for our 
two cell lines, U87mg and DAOY, under dcEFs. However, this seems to show that by 
plating cells in conditions where their phenotype is already highly invasion and 
directional (outward from the center of the spheroidal aggregates), can provide a baseline 
of motile behavior, useful for better remove the background of standard motility 
processes that are not specific to electrotaxis. 
In order to investigate more deeply into the dcEF-mediated cellular signaling, we 
performed RNA-SEQ, taking a temporal snapshot of the bulk transcriptome as the dcEF 
was applied. In our analysis, we found many pathways that were significantly impacted 
by the dcEF, ranging from chemotaxis, to growth factor signaling, to intermediate 
signaling activity of the PI3K and mTOR pathways. We saw enrichment and 
overrepresentation of spliceosome and RNA localization pathways, and ATPase 
regulation. Yet, just because a pathway is over-represented or enriched does not 
guarantee it will be causally linked to electrotaxis. Thus, in the next chapter, we attempt 





CHAPTER 4. ASSESSMENT OF THE ROLE OF SELECT 




Our transcriptomic analysis provided numerous hypotheses that require further 
validation. In this chapter, we aim to test a select few of these, in order to determine 
whether what we have seen in terms of gene expression is causally linked to electrotaxis. 
For simplicity, we have first constrained our inquiry to inhibition studies that can 
be performed with the mere addition of a pharmacological agent. Secondly, we have 
chosen targets using the PI3K pathway as a nexus, since many of our transcriptomic 
findings, as well as previous electrotaxis studies, have pointed to this pathway as an 
intermediate regulator for transducing the sensing of a dcEF into the persistent and 
directional migration of a cell. The inhibitor targets we have chosen are displayed in 




Figure 23. Abridged pathway network for selected targets. Inhibited components are 
highlighted in blue. Data obtained from multiple KEGG pathways [Kanehisa, 2000]. 
 
 
Table 6. Pharmacological Inhibitors used to explore electrotaxis pathways. Note, 
some compounds were used at multiple doses (highlighted in red). 
Compound CAS# Target(s) Dose(s) (uM) 
Isoginkgetin 548-19-6 pre-mRNA splicing 33 
AZD8931 848942-61-0 EGFR, ErbB2/3 1, 10 



























































Table 6 (continued) 
Bosutinib 380843-75-4 Src, Abl 1 
KU-0063794 938440-64-3 mTORC1/2 2.5 
MK-2206 1032350-13-2 Akt1/2/3 2 
Foretinib 849217-64-7 Met, KDR, Tie-2, FLT4 0.5 
PD0325901 391210-10-9 MEK 0.5 
LY294002 154447-36-6 PI3Kα/δ/β  2, 20 
BEZ235 915019-65-7 PI3Kα/δ/β/γ, mTOR, ATR 0.025, 0.25 
Rapamycin 53123-88-9 mTOR 0.1 
Erlotinib 183319-69-9 EGFR 5, 50 
CZC24832 1159824-67-5 PI3Kγ 1 
Mubritinib 366017-09-6 ErbB2 1 
Y-27632 129830-38-2 ROCK1/2 10 






4.2 Materials & Methods 
4.2.1 in vitro Cell Culture and Cell Lines 
U87mg (human glioblastoma, ATCC HTB-14) cells were obtained from ATCC. 
DAOY (human medulloblastoma, ATCC HTB-186), and MCF-7 (human 
adenocarcinoma, ATCC HTB-22) cells were obtained from the Duke University Cell 
Culture Facility, all originally sourced from ATCC. All cells were maintained at 37ºC 
with 5% CO2 in Dulbecco’s Modified Eagle Medium (Cellgro 15-017CV) with 10% fetal 
bovine serum (Gemini 900-108), 1% L-Glutamine (Lonza 17-605F), 1% Non-essential 
amino acids (Cellgro 25-025-CI), and 1% penicillin-streptomycin (Corning 30-001-CI). 
Cells were passaged before confluence using 0.25% Trypsin-EDTA (gibco 25200-056). 
4.2.2 Pharmacological Inhibitors 
Inhibitors used (listed in Table 6) were obtained from SelleckChem, with the 
exception of Isoginkgetin, which was purchased from Sigma-Aldrich. Doses were 
selected based on literature and experimental data provided by SelleckChem (see 
Appendix C, Table 13). Inhibitors were solubilized in dimethyl sulfoxide (Sigma-
Aldrich, D2650) according to manufacturer instructions and stored in high-concentration 
aliquots at -80ºC prior to making working dilutions with cell culture media, which were 
stored at -20ºC for no more than one month prior to experiments. Working solutions were 




4.2.3 Inhibition/Electrotaxis Assays 
U87mg or DAOY spheroidal aggregates were plated in electrotaxis chambers and 
dcEFs were applied as described in Chapter 2. However, for conditions with inhibitors, 
appropriately concentrated solutions were added immediately before matrigel was added 
to the cell-aggregates/media solution. Cells were again given 24h in matrigel (and 
inhibitor, if specified) before application of dcEF. Analysis of spheroidal aggregates was 
performed as described in Section 2.2.8. 
4.2.4 Microscopy 
Images were taken with a Leica DMi8 with Leica Application Suite X tile scan. 
Plates were all aligned in the microscope such that the anodal side (direction toward 
positive battery terminus) is to the left of the image. Z plane focus was set to the middle 
depth of the channel.  
4.2.5 Viability Assays 
For our initial inhibitor studies, viability assays (see Appendix C, Figure 43) were 
performed using Cell-Counting Kit 8 (CCK8) (Dojindo, CK04-01). 5000 cells were 
plated in test wells of a 96-well plate (biological replicates, n=4). Cells plated at densities 
of 5000, 2500, 1250, and 0 without inhibitors, as well as blank, media-only wells, and 
5000 cell wells with 1% dimethyl sulfoxide (Sigma-Aldrich, D2650) were used as 
controls. Cells were incubated with inhibitors for 24h before addition of CCK8 solution 
for 1h before imaging on a plate reader (SpectraMax i3x, Molecular Devices) at 450nm 
absorbance. 
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4.2.6 Flow cytometry 
For ErbB2 cell surface expression, U87mg cells were plated as 2D dispersed, 3D 
dispersed, and as spheroidal aggregates with and without matrigel. Cells and aggregates 
were trypsinized and stained in phosphate-buffered saline (Corning 21-040-CV) with 
10% fetal bovine serum (Gemini 900-108) and 0.09% sodium azide (Sigma-Aldrich, 
S2002). ErbB2 expression was measured using 1:20 dilutions of APC/Fire 750 anti-
human CD340 (BioLegend 324421) and APC/Fire 750 mouse IgG1, κ isotype 
(BioLegend 400195) as negative control. MCF-7 cells, known to have elevated ErbB2 
expression, plated as 2D dispersed were used as positive control for CD340. Cells were 
analyzed on a Novocyte 2060 flow cytometer. All flow cytometry data analysis was 
performed using FlowJo vX.07. 
4.2.7 Graphing and statistics 
All graphs and statistics analysis were done with Python (v2.7.x, Python Software 
Foundation, Anaconda Distribution) or Prism 7 (Graphpad Inc.) unless otherwise 
specified. The statistical methods used are reported for each result, in place. α=0.05 
unless otherwise specified. 
4.3 Results & Discussion 
We characterized the invasive responses of DAOY and U87mg cellular aggregates 
under exposure to various pharmacological inhibitors with and without dcEF. Data is 
provided in the appendix for the proportional change in spheroidal bounding box for the 
controls without dcEF, from 24h to 48h after exposure to each inhibitor (Appendix C, 
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Figure 44). Only rapamycin’s effect on the U87mg cells was found to be significantly 
different than controls (p=0.0039) with a negative proportional change in area over that 
time period. Additionally, viability data is also provided in the appendix for our initially 
tested inhibitors (Appendix C, Figure 43). The mTOR1/2 inhbitor, KU-0063794, 
significantly affected viability over 24h exposure for both U87mg and DAOY cells, 
though it was at a level consistent with the amount of growth for no additional 
proliferation, and morphologically, the cells did not appear to be distressed. Similarly, the 
pan-AKT inhibitor, MK-2206, had a similar outcome for the U87mg cells. It is important 
to note these findings as it may constrain our claims when it comes to the electrotactic 
effects on the cells with those inhibitors. 
4.3.1 PI3K Signaling Inhibition 
The PI3K pathway has been previously studied in electrotaxis, as mentioned above, 
and is of particular interest with respect to the hypothesis that electrotaxis is just another 
form of chemotaxis—the notion that electrotaxis is just electrophoresis of extracellular 
macromolecules forming a signaling gradient. The pathway is also important for the 
production and maintenance of intracellular signaling gradients, and is part of the 
signaling that often impacts the specific directionality of a given cell. Thus, we are 
interested in determining whether and how this pathway impacts either of the cell lines 
we have been studying. 
Our first set of inhibitors target the PI3K pathway directly. For DAOY cells, 
neither pan-PI3K inhibitor, LY294002 (2 µM) nor BEZ235 (25 nM), appeared to affect 
the electrotactic bias (Figure 24). 
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Figure 24. PI3K inhibitors for DAOY cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) LY294002 (2 µM) ***p=0.0003, **p=0.0020, ns=not significant 
(b) BEZ235 (25 nM) *p=0.0112, ****p<0.0001, ns=not significant (c) DAOY data 
without inhibitor compounds, redisplayed from section 2.3.6. Two-way ANOVA, Holm-
Sidak post-hoc. Mean±SEM shown. 
 
Although direct inhibition of PI3K was not impacted for DAOY, we continued our 
study by moving downstream to the mTOR pathway, which is also involved in many 
aspects of cell growth and invasions, sometimes independently of PI3K signaling. The 
mTOR inhibitor, rapamycin (100 nM), appeared to increase overall outward growth of 
the DAOY cells, however the anodal bias was still preserved (Figure 25a). Inhibition of 
mTORC1/2 with KU-0063794 no longer exhibited an anodal bias, however this was one 
of the conditions were viability was affected, and there appears to be an overall decrease 
in outward frontier growth (Figure 25b). 
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Figure 25. mTOR inhibitors for DAOY cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) Rapamycin (100 nM) **p=0.0014, *p=0.00465, 
****p<0.0001, ns=not significant (b) KU-0063794 (2.5 µM) **p=0.0057, *p=0.0351, 
ns=not significant (c) DAOY data without inhibitor compounds, redisplayed from section 
2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. Mean±SEM shown. 
 
We also tested DAOY cells against PI3K upstream and downstream targets, but 
neither IGF inhibition with OSI-906 (1 µM), nor pan-AKT inhibition with MK-2206 (2 




Figure 26. IGF/AKT inhibitors for DAOY cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) OSI-906 (1 µM) **p=0.0034 (orthogonal), **p=0.0013 
(cathodal bias), ****p<0.0001, ns=not significant (b) MK-2206 (2 µM) **p=0.0040, 
****p<0.0001, ns=not significant (c) DAOY data without inhibitor compounds, 
redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. Mean±SEM 
shown. 
 
However, unlike the DAOY cells, the U87mg cells appear to require aspects of 
the PI3K signaling pathway for electrotaxis. Pan-PI3K inhibition resulted in a loss of 
significant difference in the outward movement of the cathodal frontier, and, although it 
was still significantly different, the cathodal bias under LY294002 (2 µM) inhibition 
appeared slightly diminished relative to no inhibitor controls (Figure 27). Surprisingly, 
BEZ235 (25 nM) inhibition led to a small significant difference in cathodal bias, but the 
directionality was now slightly anodal. 
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Figure 27. PI3K inhibitors for U87mg cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) LY294002 (2 µM) *p=0.0269, ns=not significant (b) BEZ235 
(25 nM) *p=0.0306, ns=not significant (c) U87mg data without inhibitor compounds, 
redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. Mean±SEM 
shown. 
 
A follow-up study was run with the same inhibitors (LY294002 and BEZ235), but 
this time with 10x higher dose (Figure 28). The results for LY294002 (20 µM) were 
consistent with the smaller dose, and seemed to have no overall effect on the cathodal 
bias. For BEZ235 (250 nM), the bias was no longer anodal, however, any electrotactic 




Figure 28. PI3K inhibitors at increased dosage for U87mg cells. 24h hours after dcEF 
(stim) or controls without dcEF (CTL) (a) LY294002 (20 µM) **p=0.0015, ns=not 
significant (b) BEZ235 (250 nM) ns=not significant (c) U87mg data without inhibitor 
compounds, redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. 
Mean±SEM shown. 
 
There are only a few targets that don’t overlap between LY294402 and BEZ235, 
one of those being PI3Kγ, unique from other PI3Ks in that it is primary an intermediate 
in the G-protein coupled receptor pathway (GPCR)—whereas PI3Ks α, β, and δ are more 
strongly tied to receptor tyrosine kinase signaling. We used the PI3Kγ-specific inhibitor, 
CZC24832 (1 µM) to test the hypothesis that this was the particular target that was 
necessary for producing an electrotactic bias (Figure 29), and indeed, specific inhibition 
of PI3Kγ appeared to also obliterate any electrotactic bias. This strongly suggests that 
PI3Kγ signaling and potentially upstream signaling from GPCRs play a role in the 
electrotaxis of U87mg cells. This finding is also strengthened by earlier evidence that 
PI3Kγ is crucial for cathodal electrotaxis, where Zhao, et al., showed growth attenuation 
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in dcEF-assisted wound healing for PI3Kγ-knockout murine cells relative to wild-type 
cells [Zhao, 2006]. 
 
Figure 29. PI3Kγ inhibitor for U87mg cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) CZC24832 (1 µM) ns=not significant (b) U87mg data without 
inhibitor compounds, redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak 
post-hoc. Mean±SEM shown. 
 
We continued our exploration of U87mg PI3K signaling’s role in electrotaxis 
with the finding that inhibition of mTOR and mTORC1/2 both led to abrogation of any 
electrotactic bias (Figure 30) as well as pan-AKT inhibition (Figure 31b). IGF inhibition 
did not impact cathodal bias (Figure 31a), which was expected as IGF signaling requires 
the PI3K pathway that includes PI3Ks α, β, and δ.  
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Figure 30. mTOR inhibitors for U87mg cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) Rapamycin (100 nM) ns=not significant (b) KU-0063794 (2.5 
µM) ns=not significant (c) U87mg data without inhibitor compounds, redisplayed from 
section 2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. Mean±SEM shown. 
 
 
Figure 31. IGF/AKT inhibitors for U87mg cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) OSI-906 (1 µM) *p=0.0479, ns=not significant (b) MK-
2206 (2 µM) ns=not significant (c) U87mg data without inhibitor compounds, 





4.3.2 ErbB signaling inhibition 
Another pathway for which we observed broad regulatory changes in our RNA-
SEQ data was the ErbB pathway. This family of surface receptors is known to form 
hetero- and homo-dimers on the cell surface as sensors for various ligands. EGFR has 
been previously studied for its role in electrotaxis, as mentioned above, yet the other 
ErbB isoforms have not. We began our study by targeting 3 of the 4 main ErbB2 
isoforms, EGFR (or ErbB1), ErbB2 (or HER2), and ErbB3 (or HER3).  
Inhibition of ErbB signaling with neither Erlotinib (5 µM) nor AZD8931 (1 µM) 
seemed to affect the electrotactic bias of DAOY cells (Figure 32). However, the outward 
growth of each frontier was greatly diminished relative to non-inhibitor controls, yet 
since the electrotactic bias was still in place, this could merely be due to a diminished 
source of general growth signal from the ErbB receptors. 
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Figure 32. ErbB inhibitors for DAOY cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) Erlotinib (5 µM) ***p=0.0004, *p=0.0127, ****p<0.0001, 
ns=not significant (b) AZD6931 (1 µM) **p=0.0014, ns=not significant (c) DAOY data 
without inhibitor compounds, redisplayed from section 2.3.6. Two-way ANOVA, Holm-
Sidak post-hoc. Mean±SEM shown. 
 
The U87mg cells appeared to be unaffected by EGFR inhibition, however, the 
cellular aggregates grew no differently than controls with the pan-ErbB inhibitor 
AZD8931 (1 µM), and had lost their cathodal bias entirely (Figure 33). Testing both 




Figure 33. ErbB inhibitors for U87mg cells. 24h hours after dcEF (stim) or controls 
without dcEF (CTL) (a) Erlotinib (5 µM) **p=0.0016, ****p<0.0001, ns=not significant 
(b) AZD6931 (1 µM) ns=not significant (c) U87mg data without inhibitor compounds, 





Figure 34. ErbB inhibitors at increased dosage for U87mg cells. 24h hours after dcEF 
(stim) or controls without dcEF (CTL) (a) Erlotinib (50 µM) *p=0.0278, ***p=0.0004, 
ns=not significant (b) AZD6931 (10 µM) ns=not significant (c) U87mg data without 
inhibitor compounds, redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak 
post-hoc. Mean±SEM shown. 
 
We were unable to procure an inhibitor for ErbB3-specific inhibition, but we did 
attempt to determine whether ErbB2-specific inhibition resulted in loss of electrotactic 
bias, and surprisingly, it did (Figure 35a). This is notable, because U87mg cells are 
generally considered ErbB2-negative or ErbB2-weakly-expressing [Mineo, 2004]. We 
hypothesized that perhaps the U87mg cells, as some tumor cells have been shown to do 
previously [Pickl, 2009], up-regulated their ErbB2 expression when they were plated in 
3D or as aggregates, which would also explain the tempered electrotactic response we 
observed for 2D-dispersed scenarios. This was not the case however, as flow cytometry 
of the U87mg in 2D vs. 3D, dispersed vs. aggregated, yielded no change in ErbB2 
expression relative to an isotype negative control, and did not approach the signal of 
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ErbB2+ MCF7 breast cancer cells (see Appendix C, Figure 45). Lastly, inhibition of 
EGFR and ErbB4 did not impact U87mg electrotactic bias (Figure 35b).  
It remains unclear how such a low expression of ErbB2 in U87mg cells could 
affect their ability to electrotax, and further it is surprising that no other tested ErbB 
family member was associated with this process, as ErbB2 homodimers are orphan 
receptors with no known ligand or functional input [Brennan, 2000]. Overexpression of 
either ErbB2 or ErbB3 can lead to an increased anodal electrotaxis in breast tumor cells, 
though it has yet to be shown what dimerization was occurring in those cells [Pu, 2007]. 
While ErbB3 was not directly tested in our assays, U87mg cells are known to have little 
or no ErbB3 expression [Carrasco-Garcia, 2011], and given that inhibition of EGFR and 
ErbB4 had no impact on electrotaxis, the evidence points to a ErbB2-specific pathway. 
Further study will be required in order to better piece apart: (a) whether the ErbB2 
proteins are re-coordinated on the cell surface in response to a dcEF; and (b) what forms 




Figure 35. Additional ErbB inhibitors for U87mg cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) Mubritinib (1 µM) ns=not significant (b) AZ5104 (6 
nM) *p=0.0386, ns=not significant (c) U87mg data without inhibitor compounds, 
redisplayed from section 2.3.6. Two-way ANOVA, Holm-Sidak post-hoc. Mean±SEM 
shown. 
 
4.3.3 Additional inhibition targets 
We tested a few additional inhibitors for various targets that were found to be 
differentially-regulated after dcEF in the RNA-SEQ data. Both the Src and HGF 
pathways are of interest in that their activity would support a chemotactic-overlap 
hypothesis for electrotaxis. The Src/Abl pathway acts upstream of PI3K and receives 
input from a number of receptor molecules including EGFR, signals of oxidative stress, 
and growth factors [Greuber, 2013]. Our RNA-SEQ analyses produced several 
significantly enriched gene sets for ERK signaling, which has also been previously 
implicated in electrotaxis [Tsai, 2013], thus we have also chosen, PD0325901, a MEK 
inhibitor that acts upstream of ERK signaling.  
 90 
We saw numerous gene sets across both cell lines suggesting that HGF and VEGF 
signaling we differentially regulated under dcEFs thus we have included an ATP-
competitive inhibitor of both HGFR and VEGFR (mostly for MET, KDR, TIE2, and 
FLT4). We also saw much evidence pointing to dcEF-induced RNA localization and 
splicing. While inhibition of RNA localization is beyond the scope of simple 
pharmacological inhibition, we were able to perform a cursory test on general inhibition 
of RNA splicing with isoginkgetin [O’Brien, 2008]. 
Both inhibition of MEK with PD0325901 (500 nM) and Src/Abl with Bosutinib (1 
µM) in DAOY aggregates led to a loss of significant different in anodal bias relative to 
controls, however, this may be a technical/statistical artifact, because all but two of the 
replicates for each had an anodal bias (Figure 36). Inhibition of the pre-spliceosome with 
isoginkgetin (33 µM) had no effect on DAOY electrotactic bias, nor did inhibition of 
HGF/VEGF signaling with Foretinib (500 nM). Since no chemotactic signaling pathway 
we inhibited was observed to have an effect on DAOY electrotactic bias, we wondered if 
the mechanism was instead driven by chemorepulsion on the cathodal side. However, this 
hypothesis was quickly nullified when inhibition of ROCK1/2 with Y-27632 (10 µM) led 
to a 2.8-fold increase in anodal bias. 
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Figure 36. Additional inhibitors for DAOY cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) Bosutinib (1 µM) **p=0.0035, ns=not significant (b) 
Foretinib (500 nM) **p=0.0016, ****p<0.0001, ns=not significant (c) DAOY data 
without inhibitor compounds, redisplayed from section 2.3.6. (d) PD0325901 (500 nM) 
**p=0.0058, ****p<0.0001, ns=not significant (e) Isoginkgetin (33 µM) ***p=0.0006, 
ns=not significant (f) Y-27632 (10 µM) *p=0.0279 (anodal), *p=0.0472 (orthogonal 
bias), ****p<0.0001, ns=not significant. Two-way ANOVA, Holm-Sidak post-hoc. 
Mean±SEM shown. 
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For the U87mg aggregates, of the four additional inhibitors we tested only Src/Abl 
inhibition with Bosutinib (1 µM) had any effect on the overall cathodal bias (Figure 37). 
Though, this is particularly interesting with respect to our findings with ErbB inhibition, 
as Src is known to interact with ErbB2 and ErbB3 complexing [Ishizawar, 2007]. Yet Src 
and Abl are, like mTOR and AKT, broadly connected to signaling pathways for many 
cellular functions, and whether Src, ErbB2/3, mTOR, AKT, and PI3Kγ actually forms a 




Figure 37. Additional inhibitors for U87mg cells. 24h hours after dcEF (stim) or 
controls without dcEF (CTL) (a) Bosutinib (1 µM) ns=not significant (b) Foretinib (500 
nM) **p=0.0013, ns=not significant (c) U87mg data without inhibitor compounds, 
redisplayed from section 2.3.6. (d) PD0325901 (500 nM) **p=0.0015, ns=not significant 
(e) Isoginkgetin (33 µM) ****p<0.0001, ns=not significant. Two-way ANOVA, Holm-
Sidak post-hoc. Mean±SEM shown. 
 
4.4 Conclusion 
Overall, while DAOY cells did not appear to be affected by a loss of PI3K, mTOR, 
IGF, or AKT signaling, the U87mg cellular aggregates lost their cathodal bias when 
PI3Kγ was inhibited, yet other PI3Ks (α, β, and δ) do not appear to be regulating 
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electrotaxis. mTOR and AKT also appear to be part of the electrotactic response in 
U87mg cells, though if and how they are connected to PI3Kγ requires further study, as 
well as determining what input to PI3Kγ is driving the response and why it induces a 
cathodal response in these particular cells. mTOR and AKT are known to be connected 
signaling pathways, but both also have broad signaling connectivity across the spectrum 
of cellular function, thus confirming how the electrotactic signal propagates through the 
PI3K/AKT/mTOR network also demands further study. 
The ErbB pathway also appeared to be required for electrotaxis, as inhibition of 
ErbB2 and potentially ErbB3 was able to attenuate the cathodal bias to no different than 
controls without dcEFs. This was surprising as ErbB2 expression in U87mg cells is 
known to be low, and we did not see an impact to this based on our variety of plating 
formats. Which particular hetero- and homo-dimers of ErbB2 and ErbB3 are specifically 
involved requires further study, as well as whether these receptors are undergoing 
electrophoresis and asymmetrically expressed, as EGFR was found to be in previous 
electrotactic studies [Wu, 2013].  
None of our additional four inhibitors for Src/Abl, MEK, pre-spliceosome, or 
HGF/VEGF signaling seemed to have much effect on DAOY cells. However, the 
inhibition of ROCK1/2 did dramatically increase the DAOY anodal bias, suggesting that 
future studies should examine the balancing of various GTPases as a way to attenuate or 
enchance electrotaxis in these cells.  
For the U87mg aggregates, only the Src/Abl inhibitor was able to remove the 
cathodal bias. This interesting in that, although Src is broadly connected to many cellular 
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functions, it is known to be connected to the other targets we verified to be in part 




CHAPTER 5. FUTURE DIRECTIONS 
The ability to harness and to better understand electrotaxis could have broad 
implications for many biomedical enterprises including advances primarily in control of 
cellular growth for tissue engineering, wound healing, and cancer therapy. Further, with 
the rising ubiquity of electroceuticals, and therein the rise in available technologies, and 
methods, and the overall increase in interest in electrical modes of therapy, holds promise 
that we may soon see clinical applications of electrotaxis. There is however, much work 
to move our understanding of electrotaxis forward, to a level commensurate with 
clinically-viable technologies. 
Several studies could immediately follow from the work we have presented in this 
thesis. The PI3K, AKT, mTOR, and Src signaling pathway are densely connected to 
many cellular processes, and the more we can understand their interconnectivity under 
dcEFs, the better we can hone in on the particular systems that can sense dcEFs, and 
those that can translate that signal into persistent direction motility. Additionally, the 
question of how the ErbB2, and possibly the ErbB3 receptors fit into this. Are they acting 
as electrical sensors, possibly altering their confirmation or complexing based on 
transmembrane voltage? Are the relevant signaling ligands being electrophoresed, or are 
the receptors? Additionally, in our RNA-SEQ data we observed many other potential 
membrane-bound effectors that could also be involved in this process including TGFB, 
WNT, and NGF and are ripe for successive inhibition studies.  
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Overall a broader RNA-SEQ would be helpful to enable a better refinement of the 
search for electrotactic mechanisms. We only performed RNA-SEQ using the DAOY and 
U87mg and using bulk multi-cellular samples. The addition of more cell lines, and/or the 
inclusion of primary tumor samples would enable improved differential analysis, to help 
hone in on conserved electrotaxis mechanisms, as well as to enable more clustering-based 
approaches to find differentially expressed gene sets that map to particular types of 
observed electrotactic responses. Single-cell RNA-SEQ may also be of interest, 
particularly for segmenting population-level studies, as it was seen in Cohen, et al.,that 
leader and follower cells both responded differently to dcEFs [Cohen, 2014]. 
There also remains the yet unanswered challenge of how either a material substrate, 
or plating dimensionality drives different electrotaxis responses. This will be important, 
especially if electrotaxis ever finds its use in clinical applications, as the mapping of how 
an explant behaves in vitro, must reliably correspond to its expected patient-in situ, lest 
the tumor be driven in the wrong direction. 
When considering an actual therapeutic application of electrotaxis, a few truly 
powerful concepts could be realized. If it is the case that (i) cancer cells selectively 
respond to electrotaxis more than noncancerous cells; and (ii) this process invokes 
changes in specific signaling pathways; then electrotaxis could be a path to selective 
chemotherapeutics or a way to increase chemosensitivity. This however, depends largely 
on a more advanced molecular-biological understanding of electrotaxis for each target 
cell types, as well as the availability of therapeutic compounds that target those pathways. 
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Electrotaxis could also be used therapeutic with the concept of exvasion, introduced 
by Jain, et al., through the use of physical conduits, containing a particular microtopology 
that encourages exvasion toward a specified site [Jain, 2014]. dcEFs could be applied in 
integration with these conduits, or perhaps even as electrode montages that don’t require 
any particular topology to exvade tumor cells. One could even envision electrode 
montages that issue a lensed electrical field that could aggregate a diffuse tumor toward a 
surgical site. Or perhaps such an electrotaxis lens could be turned inward on the tumor, 
forcing its invasive growth toward perpetual necrosis and implosion. 
There is however one safety concern that must be addressed before dcEFs that 
provide electrotactic cues can be applied in long-term use. Eventually any stable dcEF 
source will produce non-faradaic charge transfer, an electrochemical phenomenon that is 
known to cause many non-biocompatible byproducts [Merrill, 2005]. In our experiments 
we use exchangeable salt-bridges to mitigate this issue, but continuously having to 
replace part of a medical implant every day could be infeasible. One way to circumvent 
this issue would be to use an asymmetric, biphasic dcEF, which has been previously 
shown effective at producing electrotaxis of neural precursor cells [Babona-Pilipos, 
2015]. In fact, modulating the dcEF may be add even more therapeutically-desirous 
effects, as was seen in Hart, et al., where adding alternating current to a dcEF produced 
an enhancement in keratinocyte electrotaxis [Hart, 2013]. Or perhaps the biphasic 
modulation frequency could be set at a tumor-treating field frequency? 
Eventually, we envision a flexible, electroceutical modality, where electrotaxis and 
tumor-treating fields could be combined like a therapeutic synthesizer, consolidating 
tissue, while simultaneously exvading and treating (Figure 38)—a therapy where 
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treatment signals can be combined more facilely, precisely, and potentially more safely, 
than with multiple drug combinations. This is the future of electrotaxis for biomedicine. 
 
 








APPENDIX A. QRT-PCR SUPPLEMENTAL INFORMATION 
Table 7. Candidate Gene Assay Primers & Sequences 
GENE	   NCBI	  Refseq	   Forward	  Primer	   Reverse	  Primer	  
AKT1	   NM_005163.2	   CACACACTCACCGAGAACC	   TCGTGGGTCTGGAAAGAGTA	  
CCL2	   NM_002982.3	   TAGCAGCCACCTTCATTCCC	   CCTCTGCACTGAGATCTTCCTA	  
CDC42	   NM_001791.3	   GGTGGAGAACCATATACTCTTGG	   GGATAACTCAGCGGTCGTAAT	  
EGFR	   NM_005228.3	   GCAGTGACTTTCTCAGCAACA	   TTGGGACAGCTTGGATCACA	  
FGF2	   NM_002006.4	   TGCTAACCGTTACCTGGCTA	   AAGAAACACTCATCCGTAACACA	  
FLT1	   NM_001159920.1	   TAGCTGGCAAGCGGTCTTAC	   GCAGATTTCTCAGTCGCAGGTA	  
FRK	   NM_002031.2	   TGTCAAGCTGGGGAAACCA	   TCCCATTGGTCCACGGTTTTA	  
FYN	   NM_153047.1	   GAGCCCATCTACATCGTCAC	   TTCAGAGCTCTTCCTTCTCCA	  
IPCEF1	   NM_001130700.1	   TCAGAAGCCCAGGAGGAAA	   GCATGGCCCAGATCTTTACA	  
MAPK1	   NM_002745.4	   TTGGTACAGGGCTCCAGAAA	   TCTGCCAGAATGCAGCCTA	  
MAPK14	   NM_001315.2	   GGCTCCTGAGATCATGCTGAA	   ACAGCTCGGCCATTATGCA	  
MAPK3	   NM_002746.2	   GAAGATCAGCCCCTTCGAACA	   GCAGCAGGATCTGGATCTCC	  
MAPK8	   NM_002750.2	   TCTCCAACACCCGTACATCA	   CCCTTTCATCTAACTGCTTGTCA	  
MMP1	   NM_001145938.1	   CACCTTCAGTGGTGATGTTCA	   GCTGGACAGGATTTTGGGAA	  
MMP9	   NM_004994.2	   AGTGGCACCACCACAACA	   GCAAAGGCGTCGTCAATCA	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Table	  7	  (continued)	  
PIK3CA	   NM_006218.2	   CTGCAGTTCAACAGCCACAC	   ACAGGTCAATGGCTGCATCA	  
PRKACA	   NM_002730.3	   AAGGAGACCGGGAACCACTA	   AGGGTGTGTTCGATCTGTTTCA	  
PRKCA	   NM_002737.2	   ACCATCCGCTCCACACTAAA	   AGTCGTCGGTCTTTGTCTGAA	  
PTEN	   NM_000314.4	   CCAGACATGACAGCCATCA	   AGTCTTTCTGCAGGAAATCCC	  
RAC1	   NM_018890.3	   TCACCTATCCGCAGGGTCTA	   GCCGAGCACTCCAGGTATTTTA	  
RHOA	   NM_001664.2	   GTGCCCACAGTGTTTGAGAA	   TGTGTCCCACAAAGCCAAC	  
SCN1B	   NM_000314.4	   TTCACCGAGTGGACCTTCC	   TCCAGCTGCAACACCTCA	  
SGK1	   NM_001037.4	   CTTGGGCTACCTGCATTCAC	   TGTGTCCCTGTGAATCTAGCA	  
SOD2	   NM_001024465.1	   AGGAACGGGGACACTTACAA	   TCAATCCCCAGCAGTGGAATA	  
VEGFC	   NM_005429.2	   GCCAACCTCAACTCAAGGAC	   GCATGCATTGAGTCTTTCTCCA	  
HOUSEKEEPING	  GENES	  
	   	  ACTB	   NM_001101.3	   CCAACCGCGAGAAGATGAC	   TAGCACAGCCTGGATAGCAA	  
GAPDH	   NM_002046.4	   GAACGGGAAGCTTGTCATCAA	   ATCGCCCCACTTGATTTTGG	  
IPO8	   NM_001190995.1	   TTCAGTGCAAAGGAAGGGGAA	   ACCCCTCGAGTTAATCTCTCCA	  
RPL13A	   NM_012423.3	   GAGGCCCCTACCACTTCC	   GCCGTCAAACACCTTGAGAC	  
SDHA	   NM_004168.2	   ACATCGGAACTGCGACTCA	   TTCTTGCAACACGCTTCCC	  
TBP	   NM_001172085.1	   TGCCCGAAACGCCGAATATA	   CGTGGTTCGTGGCTCTCTTA	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Table 8. Motility Gene Assay Primers  













































































































































	   	   	  NM_000601 HGF 
	  
NM_004103 PTK2B 






	   	   	   	   	  
  
NM_004048	   B2M	  
	   	   	   	  
  
NM_000194	   HPRT1	  
	   	   	   	  
  
NM_012423	   RPL13A	  
	   	   	   	  
  
NM_002046 GAPDH   
NM_001101 ACTB 	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Figure 39. Pseudo-alignment performance. (a) Percent of each sample aligned to a 
transcript in the reference. (b) Dendrogram, showing clustering of the expression profiles 
across input samples using the Euclidean distance comparing all pseudo-aligned 






Figure 40. Fold-change of most significantly differentially expressed transcripts. 
Comparing (a) U87mg, or (b) DAOY differentially expressed genes for 2h, or 8h of dcEF 
relative to 0h unexposed controls (U=U87mg, D=DAOY). Not all differentially 





Figure 41. Clustermaps for transcripts per million of differentially expressed 
transcripts after 2h. Transcripts per million are shown for (a) U87mg and (b) Daoy cells 
after 2h dcEF exposure relative to 0h unexposed controls. Each column represents 
transcripts from a single replicate sample (U=U87mg, D=DAOY). 
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Figure 42. Clustermaps for transcripts per million of differentially expressed 
transcripts after 8h. Transcripts per million are shown for (a) U87mg and (b) Daoy cells 
after 8h dcEF exposure relative to 0h unexposed controls. Each column represents 
transcripts from a single replicate sample (U=U87mg, D=DAOY). Not all differentially 
expressed transcripts are shown, as Daoy significance cutoff was set to p<0.0005 and 
U87mg to p<0.005 for improved readability. 
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Table 9. Selected over-represented pathways for U87mg 8h 
term	  ID	   term	  name	   p-­‐value	   ORA	  genes	  
GO:0060590	  
ATPase	   regulator	  




metabolic	  process	   0.000142	  
	  
ZNF207,	  ZZZ3,	  HDAC9,	  POLR1A,	  JMJD6,	  ZNF638,	  DIS3,	  DNAJA1,	  
WAC,	  DDX17,	  PPM1A,	  SRSF5,	  DNAJB6,	  EDRF1,	  RPL28,	  LUC7L3,	  
WSB1,	   CHORDC1,	   TBX18,	   SEC24A,	   CPEB4,	   FN1,	   SFPQ,	  
IVNS1ABP,	   SRSF11,	   RLF,	   RBM25,	   HSPH1,	   COPS5,	   LRIF1,	  
BHLHE41,	   CKS2,	   NCOA3,	   VAPB,	   NDP,	   ZBTB1,	   CALU,	   RBM39,	  
DNAJB1,	   PRPF38B,	   CNOT6L,	  MBNL2,	   CTTNBP2NL,	   ABL2,	  OGT,	  
HERC4,	   HMGA2,	   UPF2,	   BICD1,	   BAG3,	   HNRNPDL,	   GTF2E1,	  
NRG1,	  PPP1R15B,	  PLPP3,	  CAPN2,	  PTX3,	  RICTOR,	  STK17A,	  FRS2,	  
RPL27A,	   FNTA,	   PPIC,	   OTUD3,	   BPTF,	   JMJD1C,	   MALT1,	   NAA16,	  
SP3,	  NABP1,	   CHD2,	   ALG10B,	   CSTF3,	   FANCF,	   ZNF623,	   ZNF397,	  
POFUT2,	   MSL1,	   MGEA5,	   NCOA6,	   PRMT6,	   MAFB,	   HSPA1B,	  
ZBED6,	  TXNIP,	  PPP4R3B,	  DDX52	  
GO:0010467	   gene	  expression	   0.00000718	  
	  
ZNF207,	  ZZZ3,	  HDAC9,	  POLR1A,	  JMJD6,	  ZNF638,	  TNPO1,	  DIS3,	  
WAC,	  DDX17,	  PPM1A,	  SRSF5,	  DNAJB6,	  EDRF1,	  RPL28,	  LUC7L3,	  
TBX18,	   CPEB4,	   FN1,	   SFPQ,	   IVNS1ABP,	   SRSF11,	   RLF,	   RBM25,	  
HSPH1,	   COPS5,	   LRIF1,	   BHLHE41,	   CKS2,	   NCOA3,	   NDP,	   ZBTB1,	  
RBM39,	   DNAJB1,	   PRPF38B,	   CNOT6L,	   MBNL2,	   OGT,	   HMGA2,	  
UPF2,	   BICD1,	   BAG3,	   HNRNPDL,	   GTF2E1,	   NRG1,	   PPP1R15B,	  
PLPP3,	   CAPN2,	   RICTOR,	   RPL27A,	   BPTF,	   JMJD1C,	   MALT1,	  
NAA16,	  SP3,	  NABP1,	  CHD2,	  CSTF3,	  ZNF623,	  ZNF397,	  POFUT2,	  
NCOA6,	  PRMT6,	  MAFB,	  HSPA1B,	  ZBED6,	  TXNIP,	  DDX52	  
GO:0016071	  
mRNA	   metabolic	  
process	   0.000457	  
	  
JMJD6,	   DIS3,	   DDX17,	   SRSF5,	   RPL28,	   LUC7L3,	   SFPQ,	   SRSF11,	  
RBM25,	   ZBTB1,	   RBM39,	   PRPF38B,	   CNOT6L,	   MBNL2,	   UPF2,	  
RPL27A,	  CSTF3,	  HSPA1B,	  ZBED6	  
GO:0010468	  
regulation	   of	   gene	  
expression	   0.0000855	  
	  
ZNF207,	  ZZZ3,	  HDAC9,	  POLR1A,	  JMJD6,	  ZNF638,	  TNPO1,	  DIS3,	  
WAC,	   DDX17,	   PPM1A,	   SRSF5,	   DNAJB6,	   EDRF1,	   RPL28,	   TBX18,	  
CPEB4,	   FN1,	   SFPQ,	   RLF,	   RBM25,	   HSPH1,	   COPS5,	   LRIF1,	  
BHLHE41,	   CKS2,	   NCOA3,	   NDP,	   ZBTB1,	   RBM39,	   DNAJB1,	  
CNOT6L,	   MBNL2,	   OGT,	   HMGA2,	   UPF2,	   BAG3,	   HNRNPDL,	  
GTF2E1,	   NRG1,	   PPP1R15B,	   PLPP3,	   RICTOR,	   RPL27A,	   BPTF,	  
JMJD1C,	   MALT1,	   NAA16,	   SP3,	   CHD2,	   ZNF623,	   ZNF397,	  




Table 10. Selected over-represented pathways for DAOY 8h 




metabolic	  process	   1.2E-­‐09	  
IBTK,	   MAP3K14,	   PAFAH1B1,	   PSMB1,	   ZNF207,	   RNF216,	  
MBTPS2,	  UFL1,	  RUNX3,	  ZIC2,	  NEDD4L,	  PTCD2,	  CUL1,	  RIOK2,	  
SPEN,	   ARFGEF1,	   JMJD6,	   TRIB2,	   DAZAP1,	   DERL2,	   NUAK1,	  
ZNF638,	   POLD3,	   UBE2K,	   UBE2D4,	   RIF1,	   PUM3,	   ATP8B1,	  
CYLD,	   RRN3,	   USP40,	   NFX1,	   PPP1R15A,	   MMP2,	   PAPOLA,	  
OSBPL8,	   NLRP1,	   PSMD5,	   BTAF1,	   WAC,	   DDX17,	   PPM1A,	  
SRSF5,	   PABPN1,	   CSTF1,	   NFAT5,	   EHD4,	   GABPB1,	   IKBKB,	  
DNAJC2,	  MET,	   DNAJB6,	   AHR,	   RPL28,	   CCL2,	   PEX12,	   EFTUD2,	  
WSB1,	   CHORDC1,	   RNF141,	   CBL,	   METAP2,	   SRSF3,	   FBXL4,	  
PTP4A1,	   COL7A1,	   CBLB,	   COMMD2,	   KLHL24,	   EIF4G1,	   RAP1A,	  
SFPQ,	   IVNS1ABP,	  PRDM2,	  TROVE2,	  SRSF11,	  TSNAX,	  KLHL12,	  
CD46,	   RPA2,	   ANKRD13C,	   CPSF3,	   KBTBD7,	   TRMT1L,	   LRIF1,	  
HNRNPA2B1,	  MED13L,	   BHLHE41,	  NMI,	  AGO2,	  VAPB,	   SRSF6,	  
AHNAK,	   HP1BP3,	   ATF4,	   PUS7L,	   AJUBA,	   DTD2,	   ARHGEF6,	  
ASH2L,	   SNX9,	   RBM39,	   DNAJB1,	   RAN,	   H3F3B,	   UNK,	   CCNA1,	  
SWAP70,	   PRPF38B,	   DMTF1,	   TGFBRAP1,	   IREB2,	   TRA2B,	   SKIL,	  
FOXF2,	   FLOT1,	   CREBZF,	   MRPL15,	   PPIG,	   CNOT6L,	   SBNO1,	  
PARN,	  CLTC,	  CSNK1D,	  EPHA2,	  CYR61,	  PIGM,	  TARS2,	  PIK3R1,	  
RNF44,	  OGT,	  ERLIN2,	  UHRF2,	  LATS2,	  VEGFC,	  FOXO1,	  NR4A2,	  
GTF2E1,	   IMPACT,	   FZD7,	   UBE2Z,	   PLPP3,	   OMA1,	   FUBP1,	  
PEA15,	   MSX1,	   CGGBP1,	   U2SURP,	   PGGT1B,	   CASP3,	   EN2,	  
ORC5,	  FASTK,	  METTL2B,	  KIAA1958,	  KBTBD6,	  TAF1D,	  ZNF143,	  
RIMKLB,	   CLPX,	   CRK,	   KMT2D,	   CTNNB1,	   BDKRB2,	   MAP2K1,	  
SDC2,	   ZEB2,	   KLF13,	   HNRNPA3,	   SOCS5,	   PIK3CD,	   ATF7IP,	  
MALT1,	  BNC2,	  CHD2,	  ATR,	  ALG10B,	  CDC26,	  ANKLE2,	  THAP5,	  
TCEAL8,	   EWSR1,	   ZNF623,	   TOB2,	   ZBTB40,	   UBE2G2,	   MAFF,	  
PRPF39,	   HEXIM1,	   POFUT2,	   ENTPD5,	   TET3,	   SPRY4,	   SEMA4D,	  
AGRN,	   MSL1,	   ZBTB44,	   CD55,	   MAFG,	   PCBP2,	   IPP,	   MCMBP,	  
ZNF181,	   MGEA5,	   DDX39B,	   BAZ1A,	   MDM4,	   STK39,	   TTC37,	  
PRMT6,	   CHML,	   PBX2,	   MRPS18B,	   TRIM27,	   LGR4,	   STK38L,	  
PPP1CB,	   CCNL2,	   MRPS6,	   USP51,	   LSM14A,	   SRSF8,	   RBM8A,	  
GTF2H5,	  KMT2B,	  NEFL	  
GO:0033554	  
cellular	   response	  to	  
stress	   0.000482	  
	  
PAFAH1B1,	   PSMB1,	   MBTPS2,	   UFL1,	   CUL1,	   DERL2,	   NUAK1,	  
POLD3,	   UBE2K,	   RIF1,	   PPP1R15A,	   PSMD5,	   WAC,	   IKBKB,	  
DNAJC2,	  MET,	  DNAJB6,	  CCL2,	  CHORDC1,	  CBL,	  EIF4G1,	  SFPQ,	  
MTR,	  RPA2,	  PYROXD1,	  VAPB,	  STAU1,	  HP1BP3,	  ATF4,	  AJUBA,	  
ARHGEF6,	   ASH2L,	   DNAJB1,	   GSTM3,	   SKIL,	   FLOT1,	   CNOT6L,	  
EPHA2,	   PIK3R1,	   ERLIN2,	   FOXO1,	   NR4A2,	   IMPACT,	   FZD7,	  
PEA15,	  MSX1,	  CASP3,	  CRK,	  CTNNB1,	  BDKRB2,	  MAP2K1,	  ZEB2,	  
SOCS5,	   CHD2,	   ATR,	   ZBTB40,	   UBE2G2,	   CASP4,	   TXNRD1,	  
DDX39B,	  MDM4,	  STK39,	  PRMT6,	  USP51,	  GTF2H5,	  NEFL	  
GO:0051236	  
establishment	   of	  
RNA	  localization	   0.0447	  
	  
RIOK2,	  SRSF5,	  PABPN1,	  SRSF3,	  SRSF11,	  CPSF3,	  HNRNPA2B1,	  
SRSF6,	  RAN,	  FLOT1,	  HNRNPA3,	  ATR,	  DDX39B,	  RBM8A	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Table	  10	  (continued)	  
GO:0010467	   gene	  expression	   1.23E-­‐08	  
PSMB1,	   ZNF207,	   MBTPS2,	   UFL1,	   RUNX3,	   ZIC2,	   NEDD4L,	  
PTCD2,	   RIOK2,	   CNN2,	   SPEN,	   RAB27A,	   JMJD6,	   DAZAP1,	  
ZNF638,	  RIF1,	  PUM3,	  ATP8B1,	  CYLD,	  RRN3,	  NFX1,	  PPP1R15A,	  
PAPOLA,	   PSMD5,	   BTAF1,	   WAC,	   DDX17,	   PPM1A,	   SRSF5,	  
PABPN1,	   CSTF1,	   NFAT5,	   GABPB1,	   IKBKB,	   DNAJC2,	   MET,	  
DNAJB6,	  AHR,	  RPL28,	  EFTUD2,	  RNF141,	  CBL,	  METAP2,	  SRSF3,	  
COMMD2,	   EIF4G1,	   SFPQ,	   IVNS1ABP,	   PRDM2,	   TROVE2,	  
SRSF11,	   TSNAX,	   CD46,	   CPSF3,	   TRMT1L,	   LRIF1,	   HNRNPA2B1,	  
MED13L,	   BHLHE41,	   NMI,	   AGO2,	   SRSF6,	   AHNAK,	   HP1BP3,	  
ATF4,	   PUS7L,	   AJUBA,	   DTD2,	   ASH2L,	   RBM39,	   DNAJB1,	   RAN,	  
H3F3B,	   UNK,	   CCNA1,	   PRPF38B,	   DMTF1,	   TGFBRAP1,	   IREB2,	  
TRA2B,	   SKIL,	   FOXF2,	   CREBZF,	   MRPL15,	   PPIG,	   CNOT6L,	  
SBNO1,	  PARN,	  CSNK1D,	  CYR61,	  TARS2,	  PIK3R1,	  OGT,	  ERLIN2,	  
UHRF2,	   FOXO1,	   NR4A2,	   GTF2E1,	   IMPACT,	   FZD7,	   PLPP3,	  
OMA1,	   FUBP1,	   MSX1,	   CGGBP1,	   CHCHD4,	   U2SURP,	   CASP3,	  
EN2,	   FASTK,	   METTL2B,	   KIAA1958,	   TAF1D,	   ZNF143,	   CRK,	  
KMT2D,	  CTNNB1,	  MAP2K1,	  ZEB2,	  KLF13,	  HNRNPA3,	  PIK3CD,	  
ATF7IP,	   MALT1,	   BNC2,	   CHD2,	   THAP5,	   TCEAL8,	   EWSR1,	  
ZNF623,	   TOB2,	   ZBTB40,	   MAFF,	   PRPF39,	   HEXIM1,	   POFUT2,	  
TET3,	   SEMA4D,	   AGRN,	   ZBTB44,	   CD55,	   MAFG,	   PCBP2,	  
ZNF181,	   DDX39B,	   BAZ1A,	   MDM4,	   TTC37,	   PRMT6,	   PBX2,	  
MRPS18B,	   TRIM27,	   LGR4,	   CFI,	   PPP1CB,	   CCNL2,	   MRPS6,	  
LSM14A,	  SRSF8,	  RBM8A,	  GTF2H5,	  KMT2B	  
GO:0016071	  
mRNA	   metabolic	  
process	   0.00109	  
	  
PTCD2,	   SPEN,	   JMJD6,	   DAZAP1,	   PAPOLA,	   DDX17,	   SRSF5,	  
PABPN1,	   CSTF1,	   RPL28,	   EFTUD2,	   SRSF3,	   EIF4G1,	   SFPQ,	  
SRSF11,	   CPSF3,	   HNRNPA2B1,	   AGO2,	   SRSF6,	   ATF4,	   RBM39,	  
PRPF38B,	   TRA2B,	   CNOT6L,	   PARN,	   U2SURP,	   HNRNPA3,	  
PRPF39,	  PCBP2,	  DDX39B,	  TTC37,	  SRSF8,	  RBM8A,	  GTF2H5	  
GO:0000398	  
mRNA	   splicing,	   via	  
spliceosome	   0.00042	  
	  
SPEN,	   JMJD6,	   DAZAP1,	   PAPOLA,	   DDX17,	   SRSF5,	   PABPN1,	  
CSTF1,	   EFTUD2,	   SRSF3,	   SFPQ,	   SRSF11,	   CPSF3,	   HNRNPA2B1,	  











































































Table 12. All over-represented pathways for differentially expressed transcripts in 
{U87mg 8h} ∩ {DAOY 8h} 
term	  ID	   term	  name	   p-­‐value	   ORA	  genes	  
GO:0008380	   RNA	  splicing	   0.0258	   ZNF638,	  SRSF5,	  SFPQ,	  IVNS1ABP,	  SRSF11,	  RBM39,	  PRPF38B	  
GO:0010467	  
gene	  
expression	   0.0237	  
	  
ZNF207,	   ZNF638,	   WAC,	   SRSF5,	   DNAJB6,	   RPL28,	   SFPQ,	   IVNS1ABP,	  
SRSF11,	   LRIF1,	  BHLHE41,	  RBM39,	  DNAJB1,	  PRPF38B,	  CNOT6L,	  OGT,	  
GTF2E1,	  PLPP3,	  MALT1,	  CHD2,	  ZNF623,	  POFUT2,	  PRMT6	  
GO:0016070	  
RNA	  metabolic	  
process	   0.0057	  
	  
ZNF207,	   ZNF638,	   WAC,	   SRSF5,	   DNAJB6,	   RPL28,	   SFPQ,	   IVNS1ABP,	  
SRSF11,	   LRIF1,	  BHLHE41,	  RBM39,	  DNAJB1,	  PRPF38B,	  CNOT6L,	  OGT,	  
GTF2E1,	  PLPP3,	  MALT1,	  CHD2,	  ZNF623,	  PRMT6	  
TF:M02071_1	   Factor:	  ETV7	   0.0113	  
	  
IP6K2,	  ZNF638,	  WAC,	  SRSF5,	  DNAJB6,	  RPL28,	  WSB1,	  CHORDC1,	  GLS,	  
SFPQ,	  IVNS1ABP,	  LRIF1,	  BHLHE41,	  RBM39,	  DNAJB1,	  KIAA0907,	  CDR2,	  
OGT,	   MALT1,	   ALG10B,	   ZNF623,	   FAM120C,	   C6ORF120,	   POFUT2,	  
CHAMP1,	  PRMT6	  
TF:M07250_0	   Factor:	  E2F-­‐1	   0.00492	  
	  
ZNF207,	   IP6K2,	   ZNF638,	   GPATCH2L,	   WAC,	   SRSF5,	   DNAJB6,	   RPL28,	  
WSB1,	  CHORDC1,	  GLS,	  SFPQ,	   IVNS1ABP,	  SRSF11,	  BHLHE41,	  RBM39,	  
DNAJB1,	   KIAA0907,	   PRPF38B,	   CNOT6L,	   CDR2,	  OGT,	  GTF2E1,	   PLPP3,	  
MALT1,	   ALG10B,	   ZNF623,	   FAM120C,	   C6ORF120,	   POFUT2,	   MSL1,	  





APPENDIX C. PHARMACOLOGICAL INHIBITION 
SUPPLEMENTAL INFORMATION 
 
Table 13. Literature and Data used to determine experimental doses for 
pharmacological inhibitors. Note, when available, prior data specific for U87mg or 
DAOY cells was used. *data from Sigma-Aldrich; †reported full target inhibition; ‡50 
nM for HER2 IC50; NR: not reported 
Drug 
in vitro IC50              
(from 
SelleckChem) Previous in vitro use Reference 
Isoginkgetin 30 uM* 33um in HEK O’Brien, 2008 
AZD8931 4 nM 0.001-10 uM in various Hickinson, 2010 
OSI-906 1 uM† 0.02-0.8 uM in various Mulvihill, 2009 
Bosutinib 100 nM 250 nM in MDA Vultur, 2008 
KU-0063794 30 nM 5 uM in U373 Fan, 2010 
MK-2206 NR 1-10uM in U87 Jin, 2013 
Foretinib 0.4-165 nM .5-2.5uM in DAOY Faria, 2014 
PD0325901 2-123 nM 0.1-1uM in various See, 2012 
LY294002 0.38-45 uM 20 uM in U87/U251 Li, 2013 
BEZ235 75 nM 0.001-0.1uM in U87 Liu, 2009 
Rapamycin 0.1nM-1uM 100 nM in U87 Takeuchi, 2005 
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Table 13 (continued) 
Erlotinib 20 nM-20uM 1-10uM in U87 Fan, 2007 
CZC24832 1.5uM 1 uM in Multiple myeloma cells Piddock, 2017 
Mubritinib 0.1uM-25uM 0.25-1 uM in AML cells Ufkin, 2014 
Y-27632 0.3-1uM 10 uM in DAOY Coniglio, 2008 
AZ5104 2.6-80 nM‡ 3-80 nM in Lung Cancers Cross, 2014 
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Figure 43. Viability Assessment with Cell-Counting Kit 8 Assay after addition of 
inhibitors. Viability after 24h exposure to various inhibitory compounds for (a) U87mg 
and (b) DAOY cells. **p=0.0032, ***p=0.0002, ****p<0.0001. 100% control represents 
5000 cells initially plated, 50% 2500 cells, etc. 50%, 25%, and 0% were also significantly 




Figure 44. Proportional change in spheroid bounding box area after exposure to 
inhibitors. Samples without dcEF shown for (a) DAOY and (b) U87mg cells for the 
period 244 to 48h after exposure to inhibitor. First 2 or 3 letters of inhibitor compound 
are used as labels. **p=0.0039 
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Figure 45. Flow cytometry data for ErbB2 expression for different plating 
confirmations of U87mg cells. U87mg cells were plated onto either 2D culture plastic or 
embedded in 3D matrigel as either single, dispersed cells, or as spheroidal aggregates. 
After 24h culture in those conditions, disassociated cells were stained for CD340 (ErbB2 
marker) with APC/Fire 750 conjugated antibodies. (a) Gate history showing selection of 
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